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High-Throughput, Whole-Genome Sequencing
Abstract
Since the completion of the Human Genome Project, research focusing on the consequence of known
human genetic code has advanced by leaps and bounds. The development of personalized medicine, a
field focused on enumerating the effects of individual genetic variations, termed SNPs, has become a
reality for those researching the molecular basis of disease. With clinical correlates between genotype
and prognosis becoming ever more common, the utility of personal genetic screening has become
impossible to ignore. In this report, we present PennBio: a whole-genome sequencing company utilizing a
novel single-molecule, real time sequencing-by-synthesis technology. Using unique zero-mode
waveguides, which have revolutionized single-molecule detection, individual enzymes polymerizing novel
phospholinked fluorescence labeled nucleotides can be observed as they sequence genomic template
DNA. Modern optical techniques record these fragmented sequences, which are then analyzed by highly
efficient alignment algorithms. A personal genomic code will ultimately allow consumers to be aware of
their genetic predispositions as the medical community continues to discover them.
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Abstract
Since the completion of the Human Genome Project, research focusing on the
consequence of known human genetic code has advanced by leaps and bounds. The development
of personalized medicine, a field focused on enumerating the effects of individual genetic
variations, termed SNPs, has become a reality for those researching the molecular basis of
disease. With clinical correlates between genotype and prognosis becoming ever more common,
the utility of personal genetic screening has become impossible to ignore. In this report, we
present PennBio: a whole-genome sequencing company utilizing a novel single-molecule, real
time sequencing-by-synthesis technology. Using unique zero-mode waveguides, which have
revolutionized single-molecule detection, individual enzymes polymerizing novel phospholinked fluorescence labeled nucleotides can be observed as they sequence genomic template
DNA. Modern optical techniques record these fragmented sequences, which are then analyzed by
highly efficient alignment algorithms. A personal genomic code will ultimately allow consumers
to be aware of their genetic predispositions as the medical community continues to discover
them.

1

2

I.

Human Genomics
Traditionally, the clinical research at the heart of modern evidence-based medicine has

been performed across large patient populations. While great efforts are undertaken to ensure
that these sample groups are homogeneous, the confounding effects of individual variations are
impossible to avoid and particularly difficult to model, imbuing the conclusions of any study
with an often-significant degree of uncertainty. Rare conditions that affect only a small portion
of the population, or that are not easily identified through clinical observation, are most prone to
such mischaracterization – the very conditions that require the most specialized treatment, and
lead to the most morbid outcomes. Physicians and their patients are ultimately tasked not only
with assessing the likelihoods of these rare events, but also with evaluating the applicability of
available evidence to the specific situations at hand. The unfortunate consequences of a chance
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misjudgment are commonly seen in adverse drug reactions, treatment inefficacy, and late-stage
disease detection.
Over the past few decades, however, the rapid growth of genomics as a medically
relevant discipline has been the catalyst for dramatic advances in the practice of molecular
diagnostics. Through a greater understanding of how DNA is interpreted (transcriptomics) and
how its protein products affect cellular processes (proteomics), scientists are, for the first time,
beginning to associate abnormal physical conditions with their genetic precursors. This clinicalto-genomic mapping paves the way for a new diagnostic and prognostic paradigm – the idea of
personalized medicine. Recent translational research into the molecular basis for complex and
widespread diseases such as cancer, heart disease, and diabetes has demonstrated the
effectiveness of this approach. The physician now makes informed decisions based on the
patient’s genetic make-up rather than population-average data, allowing for increased confidence
and more favorable outcomes, overall.
One of the most visible products of personalized medicine has been the field of
pharmacogenetics, which seeks to characterize the interplay between individuals’ genotypes and
their responses to specific medications. Therapeutic parameters including dosage, side effects,
and efficacy can be predicted based on genomic data, allowing for the tailoring of an
individualized treatment regimen. The field of pharmacogenetics also sees the potential of more
rapidly identifying novel drugs for common use in humans.1 An example of the successful
application of pharmacogenetic principles is the use of warfarin. Warfarin is an anti-coagulant

4

Human Genomics

used in treating thrombosis, and is the most widely used anti-coagulant used in North America.2
Its utilization, however, is limited by potentially severe adverse reactions to the drug. Genetic
variations in the genes CYP2C9 and VKORC1 have been shown to be correlated with these
dangerous side-effects. With this novel research, new statistical models involving age, weight,
gender, and genotype are used to gauge dosage for individuals being prescribed warfarin.3
Cancer treatment has long used genetic strategies in the assessment of an individual’s
stage of tumerogenesis, enabling the selection of more effective treatment regimens. This early
form of personalized medicine is growing rapidly as techniques for characterizing the genetic
aberrations present in the cancer cells become more easily performed. Cancers, in general, are
defined by cells which have lost control of their genetic regulators, largely due to somatic
mutations, allowing them to proliferate unchecked. These mutations can vary even within certain
types of cancer, and the field of cancer genetics seeks to correlate the genetic mutations to
prognostic outcomes. With genetic screening of the cancer being targeted, physicians can start to
make prognostic and therapeutic decisions which more accurately suit the specific mutations
which have occurred. 4,5
An example of this customized treatment based on characterized oncogenesis is the
prescription of Gleevec in the treatment of chronic myeloid leukemia (CML). Some 95% of
CML cases are genetically characterized by a fusion of the BCR and ABL genes, forming the
BCR-ABL fusion protein. Gleevec targets the ABL kinase activity, and is an effective treatment
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for those with the BCR-ABL translocation, making genetic testing and often-used a diagnostic
test in treating CML.6
The application of genetic screening to treat cancer goes beyond the acute stage of the
disease. Several types of cancer, called familial cancers, are passed down through generations
from parent to child, and account for 5-10% of cancers seen in current oncology wards. Genetic
screening can assess an individual’s risk, given that the genetic mutations associated with a
certain disease have been characterized. With this knowledge at hand, preventative measures can
be taken to minimize the chance of the oncogenesis. Mutations in the BRCA1 and BRCA2 genes,
for example, are associated with increased risk of developing certain breast and ovarian cancers.
Discovery of a high-risk mutation in one or both of these genes may prompt an individual to seek
prophylactic treatment such as mastectomy or removal of the ovaries.7
Oncology is not the only medical field which can benefit from the development of
personalized medicine-based preventative treatment. Conditions such as heart disease, diabetes
and other complex syndromes such as high blood pressure and high cholesterol have been shown
to have significant genetic corollaries. Though both type I and type II diabetes are both suspected
of having genetic correlations, type II shows much stronger hereditary influence. Several genes
have been shown to be associated with the development of type II diabetes and their genetic
variations are being more specifically characterized as research continues. 8,9
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Personalized medicine is the new frontier in medical research, and in clinical practice.
From acute treatment decisions based on the molecular basis of disease to preventative medicine
based on pre-onset genetic screening, the potential benefits to society of continued genetic and
translational research are immeasurable.

I.1 Current Screening Methods
Contemporary genetic testing services – such as 23andMe and Navigenics – provide
interested consumers with information about known biomarkers, that is, physically relevant
genetic abnormalities. Numerous traits from eye color to predisposition for certain diseases to
body types can be predicted with varying degrees of confidence. These services do not attempt to
sequence the individual’s complete genome; instead, they identify single-nucleotide
polymorphisms (SNPs – pronounced “snips”) in which certain markers are exclusively targeted.
23andMe, for example, offers 500,000 SNPs associated with 109 traits at $399 per individual.
This gives the consumer price to be 0.08 cents per SNP and $3.67 per trait.
Databases such as NCBI’s dbSNP have been established to catalogue the continuously
growing number of reported SNPs discovered in current biomedical research. As of April, 2009,
the dbSNP had over 16,600,000 SNPs identified with many millions added every six months, but
few of these have been cited clinically and even fewer have been identified with definite
phenotypes. These databases, however, are science intensive, and would intimidate anyone not
extraordinarily familiar with molecular genetics, and the consumer is undoubtedly more
concerned with their phenotype – disease predispositions, for example – than their actual
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genotype – that base 53,457 in their HOXA9 gene is an adenine. Websites such as SNPedia.com
seek to connect clinical correlates to known SNP variants. SNPedia.com currently offers clinical
phenotypic correlates on 5,043 SNPs, covering 307 traits, and is growing steadily.
The limitation of these services lies in the fact that an estimated 10% of the 100 million
SNPs predicted to be present in the human genome have been identified, and an even smaller
fraction of those have been associated with some known physical manifestation.10 The SNPfocused genomics products therefore become obsolete as new discoveries are made, as they are
restricted in their usefulness to SNPs that were known at the time of the analysis. Whole-genome
sequencing operations offer a comprehensive genomic sequence which will be clinically relevant
for the rest of the consumer lifetime. By delivering an entire genomic sequence, the customer has
been granted access to at least 16 million known SNPs, and over 5,000 correlated SNPs which
make them who they are.

I.2 The PennBio Approach
PennBio is a newcomer to the biotechnology industry committed to providing
exceptionally accurate whole-genome sequencing. The primary goal of the project is to achieve
unprecedented genome throughput at a low cost. Specifically, operations have been designed to
meet an estimated demand for 3000 human genomes per year at a cost of $10,000 or less, with a
maximum start-up cost not to exceed $25 million. The rapid production and low price targets
were inspired by the Archon X Prize competition, which offers a $10 million award to the first
team to be able to meet these specified goals.
8
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A brief overview of the PennBio business plan is presented below in Table I.1, providing
an outline of the goals, scope, deliverables, and timetable for developing a system for high
throughput genomic sequencing.

Project Name

PennBio: High-Throughput Genomic Sequencing

Project Champion

Dr. John Crocker

Project Leaders

Gregory Bittle, Boris Petkov, Evan (Yonghee) Rhee, and Elliot Woods

Specific Goals

Sequence 3000 human genomes per year for no more than $10,000 per genome
sequenced, and with a start-up cost of $25 million or less.

Project Scope

In-Scope:
◊

Identify and evaluate high-throughput sequencing techniques

◊

Apply the most promising technology to provide in-house wholegenome sequencing

◊

Characterize the biological, optical, and computational methods
underlying this technology

◊

Select appropriate equipment and staff

◊

Develop a viable business model, centered around the above
production level, investment, and a genome price

Out-of-Scope:

Deliverables

Timeline

◊

Manufacturing of Zero-Mode Waveguides (ZMWs)

◊

Focused screening (such as SNP screening)

◊

The provision of genetic counseling or medical advice

◊

Market assessment and competition analysis

◊

Technical feasibility assessment

◊

Full scale manufacturing requirements and protocol

◊

Financial analysis over a 5-year project life cycle

◊

Working sequencing prototype within 12 months

◊

Scale-up operations within 2 years

◊

Full-scale production in years 3-5 with concurrent R&D

◊

Liquidate or sell the company at the end of year 5

Table I.1 Project Charter for High Throughput Genomic Sequencing
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The scope of the project includes all processing steps from DNA isolation to complete
genome reassembly. Once extracted, the DNA will be analyzed by single-molecule real time
observation, a highly efficient approach at sequencing that reads code as transcription occurs, as
opposed to the original Sanger method, which requires the amplification of the DNA prior to the
reading of sequence. The technique adopted for the process closely models that proposed by
Pacific Biosciences, who uses specially developed zero-mode waveguides (ZMW) and uniquely
labeled fluorescent nucleotides. These nucleotides will be produced on-site, as there are no
vendors that produce these specific molecules.
The production of the ZMWs, however, will be contracted out to a nanofabrication firm
in order to avoid the high capital investment in lithography equipment. Additionally, PennBio
will not offer any forms of genetic counseling of genome interpretation. This is a rapidly
evolving, research-intensive service that is best left to specialists.
The goal of the first year of the product development is the production of a working
sequencing prototype.

Once the effectiveness of the prototype is verified, scale-up and

commercial sequencing will begin in year two. The number of setups will be increased so that
the desired throughput for meeting the project goal can be met. Following year two, most of the
company resources will be dedicated to full time commercial genome sequencing and research
and development for the next innovation in genomic sequencing.
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I.3 Technology Readiness Assessment
Following the very first successful genome sequencing, each of the next attempts at
human genome sequencing strived toward reducing costs and increasing throughput. With the
Archon X Prize setting the desired bar for motivation to achieve the set requirements, the
necessary technology has to first develop in order to support the ultimate goals.

Figure I.1 Innovation map for high-throughput genomic sequencing
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With improvements in nanostructure fabrication, novel nucleotide chemistry, genomic
assembly algorithms, and optical devices capable of single molecule detection, PennBio is able
to offer sequencing which meets lofty throughput and price goals never before reached using the
SMRT chip platform. The technique requires a relatively low reagent volume, reducing costs
significantly when compared to now-obsolete sequencing methods. Additionally, the throughput
is maximized as the DNA sequence is read while transcription occurs. In order to carry out
SMRT chip-based sequencing, the key supporting technologies of zero-mode waveguides
(ZMWs), novel fluorescent molecules, and powerful imaging instrumentation have to be
available first (See Figure I.1). Due to advances in material sciences, techniques to cheaply and
consistently produce ZMW chips make them readily available at the desired specifications. In
addition, developments in fluorophore synthesis allows the production of the key sequencing
molecules in lab. Possibly the most important development for SMRT sequencing in terms of
throughput is the development of Electron Multiplying Closed-Coupled Device cameras or
EMCCDs. The cameras allow for high resolution imaging at high frame rates necessary for the
real-time reading of massive parallel arrays of microreactors that are the key parts of SMRT.
Further improvements to this imaging technology would only serve to increase the throughput of
the sequencing techniques.
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Figure I.2 Organization of the sequencing process

At $4,000 per individual, PennBio is offering a superior and more comprehensive service
than ever before offered: for
or an estimated 0.02 cents per SNP. More importantly, as new SNPs
are discovered and new clinical correlates are published, the PennBio customer will have the
information necessary to re-examine
examine his or her genome under the guidance on a geneticist.
genet
Customers of SNP-limited
limited services, such as 23andMe,, will have to be retested in the future if
they hope to maintain an up-to-date
date genomic perspective on their current health and disease
susceptibility.
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I.4 Customer Requirements
The two main customer requirements in designing the high throughput genome
sequencing technique are high throughput and reading accuracy. In order to meet both of these
customer requirements, “New-Unique-Difficult” (NUD) concepts must be implemented. These
are addressed by critical to quality variables (CTQ) that define the core of the SMRT technology.
The main limit on this throughput is the resolution capabilities of the EMCCD in use and
the frame rate of the EMCCD at the said resolution. As resolution of the EMCCD increases, the
frame rate of the camera decreases. SMRT technology relies on recording the necessary
chemical reaction in real time. Therefore, the more reactions that can be seen by the cameras,
the higher the throughput obtained. The number of reactions that are viewed is also dependent
on the waveguide chip itself.

Customer
Requirements

CTQ Variables

Weight

Polymerase Error Rate
Reading Accuracy

EMCCD Frame Rate

0.25

Number of Waveguides
EMCCD Resolution
EMCCD Frame Rate
High Throughput

0.75
Number of Waveguides
Rate of Reaction

Table I.2 Customer Requirement This table describes the customer requirements that are met by
SMRT sequencing technology, and the CTQ variables that address the specific customer requirements.
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Since the reaction occurs on the waveguide chip, increasing the number of reaction
locations on the ZMW increases throughput capabilities. Additionally, running the reaction as
fast as possible maximizes the throughput.
In order to successfully view the reaction while maintaining reading accuracy, it is
important to maintain an EMCCD frame rate that can match the speed of the reaction. More
specifically, the frame rate of the camera must be greater than the rate of the reaction observed in
each well. A compromise must be reached between the frame rate of the camera and the
resolution that is used in order to maintain the throughput and reading accuracy, while keeping
Table I.2 in mind. Throughput and reading accuracy are in fact very tightly bound. In addition
to the compromise between EMCCD speed and resolution, the coverage of the process must be
addressed. Increasing the coverage, or amount of times the whole genome is read increases the
reading accuracy. However in order to meet this coverage requirement, the throughput must also
increase. Therefore, factors such as waveguide number and EMCCD specifications that increase
throughput are directly bound to increasing reading accuracy as well.

I.5 Unprecedented Throughput
Single-day turnaround is one of the hallmarks of the SMRT sequencing design, and plays
a vital role in setting this technology above the competition. For a given investment in detection
equipment, the limit of EMCCD efficiency is achieved by one-to-one waveguide to pixel
mapping.
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The maximum number of waveguides that can be simultaneously observed (nZMW,max) is
therefore defined by the EMCCD camera’s field of view:
nZMW ,max = 512 ⋅ 512 = 262,144

Equation I.1

Some of these pixels will be used to detect a bright pattern to which the nanopositioning stage
can align itself, and a margin of error in the alignment will be allowed. Assuming the pixels at
the extreme edges of the field of are not involved in sequencing, the actual number of ZMWs
under observation (nZMW) is:
nZMW = 262,144 − (4 ⋅ 512) + 4 = 260,100

Equation I.2

Not all of these waveguides will ultimately contain DNA polymerase molecules; rather,
the proper immobilization of an enzyme within a ZMW is a Poisson event. The probability of
single-occupancy (the only fill state that will produce a meaningful signal) achieves its
maximum at 36.8% when λ = 1. Therefore, the number of polymerase molecules that should be
applied to the chip in order to maximize single-occupancy is:
λ =1=

n phi 29
nZMW

=

n phi 29
260,100
Equations I.3, 4

n phi 29 = 260,100
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Assuming only 36% single-occupancy is achieved, the number of active ZWMs would be:
nZMW , act = 260,100 ⋅ 0.36 = 93, 636 active waveguides

Equation I.5

The polymerization rate of phi29 has been demonstrated to be no less than 4.7 bases per
second13. At this speed, the number of bases synthesized per second, per SMRT chip is:
nbp
s

= 93, 636 ⋅ 4.7 = 440, 089 bp/s

Equation I.6

This process must be sustained until a 9-fold multiplicity is generated, that is, until the total
sequenced length is equal to nine time the length of the genome, or 27 gbp. As we will
demonstrate in Chapter V, such redundancy is necessary if gaps are to be avoided. The time
necessary to accomplish the coverage goal is equivalent to the time required to sequence a single
human genome on a single SMRT chip, and is calculated to be:
(3 × 109 )(9) 2.7 × 1010
1


=
= (6135 s) ⋅ 
 = 17.0 hr
440, 089
 nbp 
 3600 s/hr 

s 
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The SMRT system is the only available genome sequencing platform that offers such low
turnaround times, without compromising quality or volume. The waveguide array not only serves
to attenuate background noise, but it also provides the geometric precision required for efficient,
single-pixel detection. Combined with a purpose-developed polymerase and powerful computing
resources, this novel sequencing technology is certainly the most promising among modern
whole-genome techniques. In the next chapter, the advantages of SMRT technology will be
examined.
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II.

The SMRT Chip Platform
Pacific Biosciences was founded in 2004 with the goal of developing a low cost, high-

throughput genomic sequencing system driven by the observation of single DNA polymerase
molecules, working continuously under realistic biological conditions11. By monitoring hundreds
of thousands of enzymes in parallel, this technique is distinguished by exceptional sequence data
quality and unprecedented throughput.
These capabilities are due in large part to “single-molecule real-time” (SMRT)
technology, which is itself a fusion of biochemistry, optical theory, and recent advances in
nanofabrication12. The physical product of SMRT technology is the SMRT chip – a single-use
19
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assay platform that makes the high-fidelity, high-parallel reads possible. Two of the most
common challenges to successful fluorescence-based assays—contiguous long sequence reads
and negligible fluorescent noise—are simultaneously overcome by this revolutionary design,
which for the first time utilizes zero-mode waveguide reaction vessels and phospho-linked
fluorescent nucleotides to obtain a high-multiplex, high signal-to-noise output of long DNA
sequences.

Figure II.1 SMRT chip with array-separation gasket (A) Macroscopic view of a waveguide array (B) Closer view –
the bright spots are flaws in the aluminum cladding (C) SEM characterization of a single cylindrical waveguide (D).

II.1 Sequencing by Synthesis
Using zero-mode waveguides (ZMW)—small aluminum wells in the bottom of the
reaction vessel which have apertures smaller than the wavelength of the biomolecules’
fluorescent emissions—signal to noise ratios become dominated by the presence or absence of
those molecules in the waveguide—see Figure II.2. Utilizing this technology, single
biomolecules can be observed in action. The concept behind single molecule real-time (SMRT)
sequencing relies on the interplay between active DNA polymerases, synthetic nucleotides, and
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the zero-mode waveguides. With some preparation, these waveguides can be populated by single
DNA polymerase enzymes immobilized in place at the bottom of the wells13.

Figure II.2 ZMW with active polymerase. Reproduced from Eid (2009).

DNA polymerases replicate DNA polymers by using single stranded DNA template
polymers and synthesizing a complementary strand using free DNA monomers known as
nucleotides, matching guanine to cytosine and adenine to tyrosine and vice versa. SMRT
sequencing relies on replacing natural nucleotides with synthetically labeled fluorescent
nucleotides. These nucleotides are fluorescent until the DNA polymerase incorporates them into
the ever-growing complementary strand. Once incorporated, the fluorescent tag is released from
the nucleotide, leaving it ‘dark’. When immobilized DNA polymerases bound to template DNA
incorporate these synthetic nucleotides into a growing complementary strand at the bottom of the
zero-mode waveguides, fluorescent emissions from the nucleotides escape the waveguide only as
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they are being incorporated into the complementary strand then go dark as their fluorescent
moiety is cleaved and diffuses from the waveguide. By labeling the four different bases with four
distinguishable fluorescent tags, emissions from the waveguide form a temporal sequence of
different wavelengths which directly reflect the sequence of the strand being synthesized and
therefore the sequence of the template strand – see figure II.3. These emissions can be recorded
with high resolution optical devices and the sequences stored for data analysis.

Figure II.3 Sequencing by synthesis process, showing nucleotide addition (1), fluorescent emission and
fluorophore cleavage (2, 3), followed by polymerase procession and addition of the next base (4, 5). The intensity
time trace is representative of time-series data generated upon signal analysis. Reproduced from Eid (2009).
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II.2 The Zero-Mode Waveguide
Existing methods for single-molecule detection, such as
fluorescence correlation spectroscopy and near-field confocal
microscopy, are characterized by observation volumes on the
order of femtoliters (10-15 liters)14. If any specific individual
molecule is to be identified with any certainty, then any
additional fluorescent species may not be present above pico or
nanomolar concentrations. While this background-minimization

Figure II.4 An illustration of a
cylindrical ZMW. Published by
Pacific Biosciences, Inc. (2008).

technique is effective, the use of unusually low ligand concentrations in an enzyme-based assay
can have undesirable effects on reaction kinetics, or even cause the reaction pathway to deviate
from its natural course. DNA polymerase, in particular, has a micromolar Michaelis-Menten
constant (Km), exhibits prohibitively slow polymerization rates at low nucleotide availability.
The zero-mode waveguide (ZMW) addresses this limitation by dramatically reducing the
observation volume, thereby allowing the use of biologically-relevant conditions.
For light of any given wavelength, an aperture can be constructed through with this light
cannot propagate15. The aperture can take on any number of geometries, and its dimensions are
functions of the wavelength of the incident radiation. The cylindrical ZMWs on the SMRT chip
are designed to be narrower than this cutoff diameter, so that the fluorophore excitation radiation
becomes evanescent upon entering, and decays exponentially with distance traveled into the
ZMW. In this way, the emission energy profile is sufficient to excite any fluorophores at the very
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edge of the waveguide, but too weak to excite the fluorescent
species in the solution above. Attainable observation volumes
are decreased from femtoliters to zeptoliters (10-21 liters),
which provides a margin to increase fluorescent species
concentration

without

contributing

appreciably

to

background.
With this knowledge of the incident energy profile, a
single DNA polymerase molecule is immobilized at the
bottom of each waveguide – precisely within the volume
under observation. As this enzyme adds fluorescently labeled
nucleotides to a template sequence, it brings them within the
observation volume, and an excitation signal is detected. The
time required to add a nucleotide to a growing strand is several

Figure II.5 A heat map of illumination
intensity (top frame). Intensity as a
function of distance into the ZMW by
radius (bottom frame). Reproduced
from Levene (2003).

orders of magnitude greater than the diffusing timescale of these molecules, enabling the
polymerization process to be clearly monitored over the constant, but low intensity, noise13.
SMRT chip production is very similar to integrated circuit fabrication, and makes use the
many of the techniques developed for this industry. With even more recent improvements in the
reliability and miniaturization of the manufacturing equipment, it has become widely available,
and the process used in zero-mode waveguide creation is now quite routine. Given the submicron

24

The SMRT Chip Platform

scale of the waveguides, an array density on the order of 106 waveguides per mm2 is easily
achieved, enabling extensive parallelization of the sequencing process.

II.3 Phospholinked Fluorophores
Sequencing techniques utilizing fluorescently labeled nucleotides are well documented
and have been robust strategies for sequencing; however these approaches have used almost
exclusively base-linked nucleotides which present many enzymatic incorporation problems
including processivity issues and overall protocol encumbrance as additional bleaching or
washing steps are necessary for longer reads.16 Not only do base-labeled nucleotides form an
altered complementary strand, which is sterically disturbed—leading to issues such as increased
dissociation events from the enzyme (lowered processivity), these steric issues also lead to active
site association issues leading to extremely hampered enzymatic kinetics. In addition, these
fluorescent tags also remain on the growing complementary strand leading to increasing
background noise levels unless bleaching steps are taken to eliminate previously incorporated
bases from the fluorescent read-out. These additional steps interrupt enzymatic activity and these
techniques are therefore characterized by relatively short read-lengths as dissociation events
become much more frequent. To address this issue, when considering high-throughput entire
genomic sequencing, an alternative approach was developed using phospho-linked fluorescently
labeled nucleotides which eliminates the issues associated with base-linked fluorophores. The
phosphodiester bonds of nucleotides are cleaved when the nucleotides are incorporated into the
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growing complementary strand, and phospho-linked fluorophores diffuse away as the cleaved
phosphate groups do.

Expected Throughput
In practice process times not equal to 24 hours would lead to undesirable
precession in the sequencing time over a period of several days. In order to keep the work
schedule constant, 24 hours must be allotted for sequencing.
The throughput goal is 100 genomes per 10 days, which is equivalent to 3000
genomes per year. Given the constraint presented above, and assuming five “sequencing
days” per week, the number of stations/chips required is:

nstations =

(10 genomes/day) ⋅ 0.8
= 13 stations
(1 genomes/(day ⋅ station))

Equation II.1

Each of these stations will consist of one SMRT chip, simultaneously observed by two
EMCCD cameras through an inverted fluorescence microscope.
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Competitive Analysis

The relatively new market for genomic sequencing is filled with opportunity for growth;
however, this opportunity opens up possibilities of competition. In order to move forward with
the business model for PennBio, it is critical to perform an analysis of the competitive
environment and the major companies that offer similar services with slightly different
techniques. Besides the SMRT technology used for PennBio’s design, three other competing
technologies have been analyzed. The companies offering these technologies are Illumina, 454
Sequencing, and VisiGen. Since genome sequencing is a relatively new market and most of the
products being offered are still in their infancy, not all of the information regarding the products,
such as potential costs, is available to the public.

27

Competitive Analysis

III.1 Illumina
Illumina relies on Solexa technology in order to sequence their
genomes. The basis of the sequencing involves fragmenting the genome
into pieces and then attaching adapters to the end of each strand. These
adaptors attach to a flow cell surface. Once the strands are attached to the
surface, they undergo many cycles of amplification until they form
clusters of up to 1000 identical copies. These copies are all single
stranded. Following this step, fluorescently tagged dNTPs with reversible

Figure III.1 Illustration of
the DNA fragment clusters
13
attached to the flow cell.

termination properties are added along with polymerase. These attach to
the end of the strands and are then emit light following laser excitation. Illumina’s imaging
technology then reads out the different wavelengths emitted for each nucleotide. This process is
repeated again until the entire strands are read. Then the fragments are assembled into a genome
sequence using an unreleased algorithm.17,18
One of the advantages of the Illumina
technology is the simplicity of the flow cell design.
There are no specific wells or beads that need to be
attached to, and the amplification of the clusters
allows for a large viewing concentration. The very
Figure III.2 The Illumina Genome Analyzer

12

nature of the clusters themselves guarantee a strong
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signal, as they are very concentrated as opposed to the single fluorescent molecule that has to be
detected for the PennBio design. Also, the optics of the system are much simpler, since the
molecules are placed arbitrarily. A major advantage that lllumina posses is an already built
sequencing station that mechanizes each sequencing step. These units will be provided to
laboratories, so that Illumina does not actually sequence the genomes, but the labs that purchase
them do.
A major disadvantage to the technology is that it has low throughput compared to
PennBio’s projected throughput. An entire genome can be sequenced on the order of weeks.
This is just the sequencing method. The actual preparation of the flow cell and amplification of
the DNA takes one business day. This is significantly longer than PennBio’s expected
throughput.

III.2 454 Sequencing
454 Sequencing is more competitive than Illumina in terms of
throughput, though not by much. Like Illumina, 454 amplifies a single
stranded molecule attached to a surface. However, the surface is a bead
that is immersed in an emulsion, creating a microreactor. These beads
are then placed in individual wells. The wells are in a PicoTiterPlates

Figure III.3 454’s
14
bead microreactor.

that are found in a Genome Sequencer FLX Instrument. Using a fluidic
assembly, the sequencer pumps nucleotides over the wells. Upon incorporation with the DNA
template, a combination of fluorescent enzymes that react with the template emits different light
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spectrums based on the nucleotide. Much like the other sequencing techniques discussed, the
light emitted is used to come up with a sequence reading. Unlike the rest of the techniques, the
454 technique adds each dNTP one at a time per cycle, and these cycles are repeated until the
entire DNA strand is sequenced. With DNA fragments of approximately 400 bp long, the
cycling slows down the sequencing time.19
In addition to this delay, the relatively short fragment length, increased time is required to
process and reassemble the genome. As it is discussed later, in the section dealing with
reassembly of the genome, shorter fragment lengths make it much more difficult and time
consuming to assemble a complete genome from fragments.

III.3 VisiGen
VisiGen is the competitor most similar to PennBio.
VisiGen uses SMRT sequencing in order to achieve their
high throughput. The major difference between the two
competing technologies is PennBio’s use of a zero-mode
waveguide. VisiGen forgoes the use of this plate and
randomly immobilizes its polymerase onto the surface of
its plate. The biomechanism for both companies use a
polymerase that allows DNA to replicate with the addition
of fluorescently tagged dNTPs. Using laser excitation, the
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Figure III.4 Basic setup for the
15
VisiGen sequencing system.
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fluorophores emit light that is detected by an EMCCD camera, as can be seen in the figure on the
left.20
Using this technique, VisiGen avoids the requirement for waveguide use. Though this
reduces the cost in purchase of waveguides, it creates several other problems. With the
polymerases randomly dispersed with no real separation, interference from other complexes
creates potential errors in the sequence read and increase the signal to noise ratio. In addition to
this, the field of view used is not maximized, as the polymerases do not necessarily line up with
each pixel, as they do in the ZMW for PennBio. As seen in Figure III.4, VisiGen uses a Bayer
color filter on its EMCCD. This dedicates at best 4 pixels per polymerase, which is half of the
resolution used by PennBio, as it is discussed later. This increases the number of microscopes
required per station or the number of stations required per genome to be sequenced, increasing
the cost well above any savings incurred from not having to purchase waveguides.
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IV. DNA Polymerization
The following chapter seeks to describe in detail the synthesis reaction contained by each
ZMWs. In order to understand the process, some fundamental biochemistry must be discussed.
To fully conceptualize the reaction taking place, let us begin by considering the reactants,
themselves. In sequencing-by-synthesis, single stranded template DNA serves as the foundation
of the reaction. It is given the name template because it serves as a guide for the synthesis of new
strands, and DNA’s unique structure makes it ideally replicated by a process so elegant, it could
only be found in nature.
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DNA’s famous double-helix structure is constructed of two anti-parallel strands of
nucleic acid polymers made from deoxynucleotides. The strands have a backbone made from
connecting ribose and phosphate ester linkages labeled from 5’ to 3’ from the carbons on the
ribose ring, like the sides of a ladder, in which the rungs are the nucleobases—guanine, adenine,
cytosine, and tyrosine. The rungs are formed as hydrogen bonding between complementary bases
connects the two phosphor-deoxyribose backbones. Adenine interacts with tyrosine as guanine
pairs with cytosine—see Figure IV.1below.

Figure XII.1 DNA's unique ladder-like structure. Detailed are the phosphate-deoxyribose backbone and
the hydrogen-bonded nucleobases complementary to one another. Reproduced from Ball (2007).
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This unique structure allows DNA to be denatured—when the hydrogen-bonding
between complementary strands is disrupted and the two strands are separated from one
another—and then new complementary strands synthesized from the two original strands,
effectively doubling the number of strands each time. Because the bases in the double-stranded
DNA are complementary to each other, each strand holds the entire code, and both strands can be
used to make entirely new, complete double-stranded DNA. In vivo this process involves a
complex interplay between many enzymes which serve distinct functional roles in constructing
new complementary strands from the template strands. In vitro, this process can be modified to
take place with the help of just one enzyme—DNA polymerase. DNA polymerase catalyzes the
addition of nucleotide triphosphates to a growing complementary strand by cleaving the
phosphate groups from the substrate. Polymerases, however, cannot construct complementary
strands de novo. They must bind double stranded DNA and build upon the complementary
strand in so-called extension reactions. To ready template strands for replication in vitro,
therefore, template strands are primed with short, single stranded DNA polymers complementary
to the beginning of the sequence to be replicated—these short nucleotide sequences are called
primers. Once primed the polymerase adds the complementary nucleotide, shifts down the DNA
and adds the next complementary nucleotide. Once the polymerase reaches the end of the
template strand, the polymerase dissociates from the newly synthesized double stranded DNA
and can complex with a new, primed template strand. This concentric-cycles scheme for DNA
synthesis is detailed in Figure IV.2.
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Figure IV.2 In vitro DNA replication using primers to allow phi29-polymerase complexing and extension of the
complementary strand.

In order to utilize this invaluable enzymatic machinery to sequence template DNA by
synthesis, several steps must be taken to prepare the reaction vessel and the starting materials.
First, an appropriate DNA polymerase must be chosen which is suited to the task of accurate,
speedy DNA replication in the manner necessary for SMRT sequencing. We show that the phi29
polymerase, from the phi29 bacteriophage, is well suited for the job. Next, the template DNA
must be prepared. Because an individual’s genome is to be the template for sequencing, a tissue
sample is needed to obtain a sample of the DNA. Using a whole-genome amplification kit
offered by Qiagen, a small amount of genomic DNA, which can be isolated from a non-invasive
cheek swab, can be amplified so that plenty of genomic template is available for sequencing. For
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the sequencing-by-synthesis reaction, suitable primers are chosen such that no sequence is biased
over others, and that the entire genome is sequenced in its entirety. The templates, primers and
polymerases are pre-bound and pre-complexed before immobilizing the polymerase into the
zero-mode waveguides. This immobilization involves several chemical treatments of the
waveguide nanostructure to ensure optimal waveguide occupancy. Lastly, the ingenious
phospho-linked fluorescent nucleotides are discussed as their unique properties and behavior as
substrates for DNA synthesis are crucial for the success of SMRT sequencing, followed by a
discussion of dissociation rates for completed synthesized strands and reassociation of new
primed-template strands, polymerization rates and error rates.

IV.1 The Phi29 Polymerase
The polymerase to be used in the SMRT system had to be chosen carefully. Dozens of
polymerases are commercially available and most have been extensively documented. Most of
these polymerases serve very specific roles: the Taq family of polymerases consists of thermally
stable polymerases and these are ideal for polymerase chain reactions in which thermo-cycling is
utilized to produce extremely high levels of amplification of template DNA; high-fidelity
polymerases are available which contain extensive 3’->5’ exonuclease activity—essentially
backward double-checking of synthesized strand—enabling the proof-reading of the strands
being synthesized to give extremely low error rates in synthesized strands; long-template
polymerases exist which are known for very high processivity – a sort of ‘polymerase endurance’
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– and very low dissociation rates between the polymerase and the template strand. These
polymerases are capable of replicating very long template strands.
The bacteriophage, phi29, is a member of a family of phages which mostly infect
Bacillus subtilis, a ubiquitous bacterium commonly found in soil. This phage carries its genetic
code in double-stranded DNA form, and its DNA polymerase has been found to be an
exceptional one.21 Because of the nature of the phage’s minimal biochemical ‘luggage’ present in
its capsule, its polymerase must be capable of replicating the genome of the phage with little of
the enzymatic support often present in prokaryotic or eukaryotic systems. The phi29 polymerase
has been found to be capable of extremely processive replication in the absence of accessory
proteins to aid in the retention of the template strand in the active site of the enzyme. In addition,
the polymerase shows strand displacement capabilities while it polymerizes making it able to
replicate strands of DNA with complementary strands still partially bound to the template strand
as well as overcome secondary structure in single-stranded DNA templates. These properties
allow the enzyme to replicate the phage’s genome without the use of primases or other accessory
proteins commonly found in genomic replication schemes and perform multi-pass replications
without dissociation with the template with just one modestly sized (66.7 kDa) monomeric unit,
further highlighting the incredible efficiency of this enzyme. 22
In addition to incredible processivity – average replication lengths of over 70 kbp are
commonly reported and values as high as several hundred kilobases have been cited in the
literature – the synthesis rates and fidelity of the enzyme are also rather impressive. Esteban,
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Salas and Blanco reported error rates as low as approximately 10-5 and polymerization rates as
high as 100 bases per second.23,24,25
In combination, these properties of the phi29 polymerase – extremely high processivity
and strand displacement capabilities with very high replication fidelity and synthesis rates –
make it an ideal candidate as the enzymatic machinery for the catalysis of isothermal single
molecule DNA replication.

IV.2 Target DNA Isolation
Genomic sequencing by synthesis relies on template genomic DNA. To isolate a sample,
the REPLI-g whole genome amplification kit by QIAGEN utilizing multiple displacement
amplification (MDA) with phi29 polymerase provides a simple and cheap method of DNA
isolation and amplification.26 Only a cheek swab from the person whose genome is to be
sequenced is needed providing a non-invasive means of collecting their genomic code. The
cheek swab collects cells from the inside of the mouth which contain whole genomic DNA. The
DNA is then isolated from the cells and amplified to ensure that enough material is present as
described in Appendix B. As shown in Figure IV.3, the REPLI-g Midi kit provides 40 µg of
genomic DNA, regardless of the amount of starting material.
The amplified genomic DNA is generally greater than 10 kbp in length and ranges from 2
to 100 kbp. And the REPLI-g Midi kit uses the same phi29 polymerase as the SMRT system,
providing the same level of fidelity as is necessary for accurate sequencing. As with the SMRT
system, the phi29 polymerase shows sequence displacement competency so that there is no
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sequence bias in the amplification.27 These properties make the product of the genomic
amplification a perfect template for SMRT sequencing.28

Figure IV.3 Yield of genomic template DNA after treatment with the REPLI-g Midi kit, as given by QIAGEN.

IV.3 Priming and Random Hexamers
With plenty of genomic DNA as a template for SMRT sequencing, the DNA must be
primed for sequencing by synthesis. There is no known DNA polymerase which can replicate
DNA from a native single strand. The phi29 polymerase requires a portion of the template strand
to be double stranded as a starting point for synthesis, as it binds complementary nucleotides to
the growing synthesized strand, so a starting synthesized strand must be bound to the template
DNA before the reaction can begin. Choosing the right primer is an extremely important task.
Because the entire genome must be sequenced, no one sequence can be biased over another. This
demands the use of random hexamers.
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Random hexamers, a collection of a six nucleotide oligonucleotides with random
sequences—designated

5’-NNNNNN-3’—have

been

used

in

sequence-independent

amplification for years and are well documented, widely available, common reagents for
unbiased amplification of DNA.29,30 Because every possible combination of nucleotides is
present in random hexamer mixes in essentially equimolar amounts, all sequences present in the
reaction vessel have the same probability of being amplified. Fidelity Systems has developed a
phi29 Random Hexamer mix optimized for sequence-independent phi29 polymerase-mediated
DNA amplification, designed by Clyde A. Hutchison and colleagues, which includes random
hexamers resistant to 3’->5’ exonuclease activity—a feature of some polymerases making them
capable of rejecting imperfect priming—providing optimized hexamer-template association
resistant to dissociation by phi29 polymerase-mediated exonuclease activity.31
Template DNA amplified with the QIAGEN MDA kit is denatured using an alkaline
denaturation as opposed to a heat denaturation for several reasons. First, phi29 polymerase is
heat sensitive and is inactivated at temperatures above 65°C, while most thermocycling-based
polymerization protocols include denaturation steps around 94-98°C. Therefore, annealing—the
term given to the association of complementary sequences to form double-strands—of primers
their templates is not possible without first inactivating the polymerase.

Second, heat

denaturation is known to degrade DNA samples and fragmented makes for poor sequencing
templates.
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The preparation of the template-primer complex is as follows. The DNA isolated with the
QIAGEN REPLI-g Midi kit is first sonicated to a mean length of 2kbp to eliminate steric issues
associated with entry of the template-polymerase complex into the waveguides. Next, the
sonicated template DNA is denatured using a 0.2 M NaOH alkaline solution. After alkaline
denaturation, the template DNA is incubated with the primer mix at a concentration of 50µM for
3-10min at 30°C.32

IV.4 Template Binding
Next, the primed template DNA is incubated at 1.5-3 molar excess with biotinylated
phi29 polymerases at 4°C for ten minutes in buffer to form the template-polymerase complex.33
Because no free nucleotides are present, the primed template DNA binds to the active site of the
enzyme but the synthesis reaction does not proceed. The template-bound polymerase must be
immobilized in the bottom of the waveguides for the synthesis reaction to be accurately observed
and recorded.

IV.5 Immobilization of the Enzyme-Template Complex
Immobilization of the polymerase requires extensive preparation of the waveguide
nanostructure. Several factors must be taken into consideration when preparing the
nanostructure. Though circular ZMWs have been used in many single-molecule detection
studies,34 their applications have been highly limited by the inability to selectively immobilize
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molecules to the observation volumes immediately above the transparent floor. To address this
issue, the dual-material nature of the ZMWs has to be exploited. Selectively reacting one of the
two materials in a derivatization reaction enables the manipulation of either of the two different
surfaces. Many factors had to be taken into consideration when designing the derivatized surface:
stability in aqueous solution, in which the sequencing reactions would take place is a high
priority; fluorescent background must be as low as possible to reduce noise in detection during
the synthesis; and adsorption of the fluorescently labeled substrates must be low to help keep
noise at a minimum. Passivation of mixed material nanostructures is an area of intensive active
research, but the most common materials are gold-on-glass based structures. 35, 36 Aluminum-onglass structures have many advantages over gold when optical confinement of the ZMWs is
considered as it has better reflectivity and a shorter optical skin depth. Aluminum, however, is
corrosive in aqueous medium.37 Organophophorus acids have been shown to react with metal
oxides, such as aluminum oxide, while not interacting with silicon dioxide surfaces in aqueous
medium, offering a method of protecting the aluminum while leaving the glass of the structure
unadultered. 38,39
To selectively passivate the aluminum from protein absorption, polyvinylphosphonic acid
(PVPA) is thermally deposited from a 2% aqueous solution of PVPA by incubation at 90°C for 2
minutes and then annealed in a dry oven at 80°C for 10 minutes.40 To test the bias of these
passivated aluminum surfaces on glass, adsorption of neutravidin as a test protein was conducted
on both PVPA treated and untreated aluminum-on-glass nanostructures and the protein
fluoresced for visualization with fluorescence microscopy. As shown in figure IV.4, the treated
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aluminum showed tremendous bias with respect to physisorbtion of neutravidin. Untreated chips
show bright aluminum squares as reflections from the metal intensify fluorescence, while treated
chips show dark aluminum squares where little physisorbtion is found.41
When treated with phi29 polymerase, similar protein physisorbtion bias was found. A
localization density ratio of over 400:1 on glass over aluminum was conferred, demonstrating the
suitable passivation of the aluminum on the ZMW nanostructures for DNA synthesis .42
Preparing the ZMW for immobilization of the polymerase on the glass of the waveguides
is further enhanced by the use of an additional biotinylated polyethylene glycol layer. The
biotinylated polyethylene glycol (PEG) polymer is deposited on the silicon dioxide by a process
known as silanization. Using Biotin-polyethyleneglycol-trimethoxysilane, the glass bottoms of

Figure IV.4 PVPA treated (bottom) verses untreated (top) whole aluminum-on-glass chips (left; scale bar, 1 mm) and
aluminum glass interfaces (right; scale bar 10 µm) with deposited fluorescently tagged neutravidin. Reproduced from
J. Korlach (2007).
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the ZMWs are effectively covered in Biotin using the PEG polymers, known commonly as
PEGylation, by a reaction between the trimethoxysilane and the silicon dioxide.
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biotinylated ZMWs are treated with streptavidin at 22°C for ten minutes at a 2-fold streptavidin
to polymerase molar excess.
Biotinylation is a process by which the coenzyme biotin—also known as vitamin B7 or
coenzyme R, molecular formula C10H16N2O3S, see figure IV.5—is covalently attached to
another biomolecule. This technique has been used extensively in laboratory research and
biomolecule preparation for decades because biotin and the avidin type proteins bind with an
incredible degree of affinity.44 The dissociation constant for biotin from avidin is ~10-15M
making it one of the strongest known non-covalent interactions.45

Figure IV.5 Biotin

Because streptavidin is a tetrameric protein which binds biotin stoichiometrically, the
protein behaves like a glue between the biotinylated glass and the biotinylated phi29 polymerase.
The ZMWs are washed with buffer to remove excess unbound streptavidin, followed by
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immobilization of the polymerase-template complex at 4°C for 15 minutes by binding
polymerase to streptavidin. Unbound complexes are washed away with reaction buffer.46
Immobilization in this manner—using biotinylation—gives orientation consistency to the
polymerases present in the ZMWs. This is extremely important for high-throughput sequencing.
Randomly distributing the polymerase molecules across the ZMWs leads to a Poisson
distribution of occupancy, and optimal loading gives only 36.8% of ZMWs with single molecule
occupancy.47 Clearly, waveguides with no polymerases will not produce reads, but also,
waveguides with two or more polymerases will give reads in which the sequences of the two
polymerases cannot be distinguished and throughput is affected. Orientation, however, is not
directed by random distribution and misaligned polymerases will not function correctly and
throughput could be highly reduced. By utilizing biotinylation binding in the bottom of the
ZMWs, Korlach, Turner and colleagues found that 82% of singly occupied ZMWs produced
full-length sequence-by-synthesis reads, greatly improving the throughput of the SMRT
sequencing system.48

46

DNA Polymerization

IV.6 Phospholinked Fluorescent Nucleotides
By labeling nucleotide bases at the terminal phosphate, see Figure IV.6 below, several
issues of processivity in fluorescence based sequencing are addressed. Because natural
polymerase activity cleaves the alpha-beta phosphoryl bond in the phosphonucelotide, the
nucleotide incorporated into the growing product strand is a completely unaltered deoxyribose
nucleic acid, and the strand grows as normal, as steric hindrance is eliminated. Furthermore, it
has been shown that extending the triphosphate moiety to four and five phosphates increased
incorporation efficiencies.49 In several kinetic studies, Korlach and associates have shown that
phi29 polymerase can, when all four dNTPs have been replaced with phospho-linked
nucleotides, perform processively over thousands of bases at kinetics reaching levels of those
associated with unmodified dNTPs—see figure IV.7. In addition, the synthesis of these special
nucleotides has been elaborated in the literature—the procedure is detailed in Appendix D.50

Figure IV.6 Penta-phosphate-linked Alexa Fluor 488
aminohexyl-O-dG5P
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IV.7 Polymerization Rate Comparison
With the primed template DNA bound to the phi29 polymerase and this complex bound
to the biotinylated glass bottom of the ZMWs, the sequencing by synthesis reaction is ready to
proceed. First, an enzymatic oxygen scavenging system, using protocatechuate dioxygenase, is
added to the array. Fluorophores are very susceptible to oxidative damage, and it has been shown
that dioxygenases added to fluorescence based single-molecule experiments greatly increase the
life of the fluorophores.51 Finally, the four phospho-labeled deoxyribose pentaphosphate nucleic
acids are added to the array along with manganese acetate to concentrations of 250 nM (each
nucleotide) and 0.5 mM respectively and the polymerization initiates at 30°C for the length of
time needed for suitable sequence coverage.
Rates of polymerization of the phi29 polymerase
utilizing

phospho-linked

nucleotides

exhibit

classic

Michaelis-Menten saturation kinetics. Consistent with
Michaelis-Menten kinetics, maximum saturation velocities,
Vmax, and substrate concentration at half-maximum velocity,
K1/2, values can be calculated for any fluorophore/nucleotide
combination and a kinetic fingerprint equation developed
for predicting polymerization velocities, Vel, as a
function of nucleotide concentration, C.

Figure IV.7 DNA products after 5 minute extension
reactions. Native dNTPs are compared to phospholinked dN5Ps and conditions with just one base-linked
dNTP alongside a negative control.
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The elongation velocity is given by:
∙
+

=

Equation IV.1

To optimize the read accuracy, nucleotide concentrations have to be carefully tuned to
optical read capabilities. Background fluorescent noise is somewhat concentration dependent,
however, the use of the ZMWs provides a wide window of concentrations which provide
acceptable signal to noise ratios. The small detection volume surrounded by reflective aluminum
limits penetrative light to no further than a few nanometers into the waveguide and additionally
limits diffusion-mediated fluorescent occupancies to the order of 2-10 µs verses nucleotide
incorporation events on the order of milliseconds, providing easily distinguishable pulses. Base
discrimination and read confidence are based on pulse and inter-pulse durations (see
fluorescence discussion below). Nucleotide concentrations of 250nM each provide an average
polymerization rate of 4.7 ± 1.7 bases/second with an acceptable error rate and signal to noise
ratio.53

IV.8 Dissociation of Synthesized Strands and Re-Complexing with
New Primed Template Strands
After a polymerase has completed synthesis of a complementary strand from a primed
template strand, the newly synthesized double strand dissociates from the enzyme and the
enzyme is left free to re-associate with another primed template and continue sequencing. The
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re-complexing of a new primed template is a diffusion-mediated event. Because the binding of
primed DNA templates to polymerases is quite an exergonic reaction,54 we assumed that any
primed-template DNA which made its way to the bottom of a waveguide containing an empty
polymerase would bind and proceed with synthesis.
To calculate the rate at which primed-template DNA enter the waveguides, Fick’s law of
diffusion was applied to free DNA molecules in solution. Fick’s law of diffusion has the form:

Equation IV.2

Where, J is the flux (in

∙

); D is the diffusion coefficient of the DNA (in

); and

is

the special derivative of the concentration gradient.
Robertson et al. have developed a correlation between DNA length and its diffusion
coefficient of the form: D = 2.3453 ∙ (

ℎ

)

.

.55 This correlation gives our

average two kilobase DNA fragments diffusion coefficients of 2.488

. This value is fixed for

our fragment length at reaction temperature.
The concentration gradient, however, is manipulatable, and it must be. In order for our
fragments to be distinguished from one another, there must be some distinguishable signal to the
recording computers that an old fragment is done being sequenced and a new one has started, or
reassembly will be unnecessarily more complicated. In this regard, we calculated the rates of
diffusion into the ZMWs for various concentration gradients. At a low limit of 0.1 ng per 50 µl
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(a lower limit based on a hypothetical failed genomic amplification using minimal genomic
template, which correlates to a molarity of 1.62 picomolar) the flux is shown to be:
=2.488

∙

.

.

×

∙

.

=

×

Equation IV.3

∙

At the high limit of 40µg per 50µl (based on undiluted amplified genomic product,
corresponding to a molarity of 0.647 micromolar) the flux is found to be:
=2.488

∙

.

.

×

∙

=

.

×

Equation IV.4

∙

When these fluxes are multiplied by the area of the waveguides (100nm in diameter yields well
areas of 7854 nm2) and Avogadro’s number (6.02 x 1023 strands of DNA per mol) the diffusion
rate into the waveguides of the DNA strands is found:

Lower Limit

Upper Limit

Diffusion Rate (strands/s)

0.00019

76.11

Dissociation/Recomplex Lag

5,256 s

0.013 s

Table IV.1 Diffusion rates calculated from correlated DNA diffusion coefficients and the consequential
lag times between dissociation of completed complementary synthesized strands and reassociation
with new primed-template DNA strands, at reasonable limits of operation.

Clearly, at the lower limit, throughput would be highly compromised, as on average, hours
would be spent waiting for free polymerases to bind new template strands. The higher limit
presents another problem, however, as lag time between fragments would be on the order of
inter-pulse widths, meaning that no distinction between the last base of a fragment completing
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synthesis and the first base of a fragment starting synthesis could be made, and the fragments
could not be separated, causing sever reassembly problems. In order to optimize distinction
between fragments yet reduce impact on throughput, DNA template concentration is chosen
where the lag time between fragments is just longer than 75% of inter-pulse durations, such that
the majority of fragments are distinguished, yet throughput is not significantly affected. Using
data collected from Eid et al., a cumulative exponential distribution was evaluated to find that
three-quarters of inter-pulse durations would be less than one second long. To then find the DNA
concentration at which mean lag time between dissociation and re-complexing events was longer
than one second, the flux has to be calculated and then the DNA concentration backed-out using
Fick’s Law:
1
1

∙

2.115 × 10
∙

1
6.02 × 10

∙

∙ 0.1

∙

1
0.007854

2.488

∙

2.115 × 10
∙

=

10
1

=

Equation IV.5

8.5

Equation IV.6

With an optimized DNA concentration of 8.5 nanomolar calculated, the final reactants can be
added and the reaction begun.

IV.9 Error Rates and Possible Sources of Error
Errors are currently on the order of 0.214%. Of these errors, the majority (44%) are
deletions. Deletions occur from incorporation events which are too short, or when inter-pulse
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durations are too short to be confidently detected. Nucleotides with no fluorescent label—so
called ‘dark nucleotides—can be sources of deletion errors however, HPLC analysis show that
the phospho-linked nucleotide composition is over 99.5% pure,56 and kinetic studies have shown
that phi29 polymerase shows no discrimination between phospho-linked and native
nucleotides.57 Additionally, statistical models predicting pulse-width distributions and projected
probabilities of pulse detection show excellent consensus with the deletion rates observed. Future
research and development efforts will focus on reducing these errors by further modifying the
enzyme to reduce the fraction of short incorporation events as well as increasing camera framerate to strengthen the resolution of inter-pulse widths.58
Insertion errors are caused mostly by dissociation of cognate nucleotides from the
enzyme before the formation of the phosphodiester bond to the growing complementary strand
resulting in duplications. As with deletions, these errors can be addressed by modifying the
enzyme to reduce the free-energy of the nucleotide substrate in the active site thereby reducing
the dissociation constant for cognate nucleotides. Mismatches were accountable to spectral
misassignments between fluorophores with close emission wavelengths. These errors can
addressed in future experiments by using dyes with more separation between emission
wavelengths, as well as increasing the camera sensitivity.59
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IV.10 Conclusions
With a waveguide of 512 by 512 ZMWs with 1 micron square pitch spacing, an area of
0.318 mm2 makes up the reaction vessel interface. With a liberal 1mm tall aqueous reaction
mixture added, our reaction volume comes to 0.318 mm3 or 0.318 µl. Once our templatecomplexed polymerase has been immobilized on our nanostrucure the reaction mixture is added
which is comprised of the following, in molar amounts shown, and the sequencing reaction
proceeds at 30°C:

Compound

Concentration

Comments

DNA

8.5 nM

Template fragments of which are replicated
forming sequencing output

Primers

50 µM

Random hexamers prime template strands for
sequencing by synthesis

dN5Ps

250 nM (each)

Substrate for nucleotide addition to growing
complementary strands

ACES

50 mM

pH buffer for biochemical reactions in the
range 6.1-7.5

Potassium Acetate

70 mM

Salt buffer

Dithiothreitol

5 mM

Reducing reagent which deprotects thiolated
DNA for efficient processivity of polymerases

Manganese Acetate

0.5 mM

Metal cation necessary for function of many
DNA polymerases

Table IV.2 Combined at 30°C, these components initiate the reaction and sequences are read at the rates
described above.
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V. Optical Detection
of Single Molecules
Several techniques exist for the focused analysis of single molecules. While varying
slightly in execution, these all derive their resolving power from the minimization of one of two
system parameters: background fluorescence, and observation volume. Either approach has a
similar effect, namely, to reduce the probability of detecting a signal from more than one
fluorescently labeled molecule at any given moment, enabling confident distinction between true
signal and background noise.
The following chapter takes a closer look at the optical system required to meet the high
throughput required for success. An analysis of the microscopic systems and the EMCCD
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cameras required is performed to make sure that the setup is feasible. A key design element of
the optical system, the use of two cameras to view the sample, is thoroughly examined, as it is
critical in increasing throughput. The remainder of the chapter looks at the capabilities of those
cameras used to determine whether or not they meet the detection requirements for successful
observation of the sample volume.

V.1 Confocal Fluorescence Microscopy
One of the most widespread methods in practice today, due to its effectiveness and
relative simplicity, is confocal microscopy14. As illustrated by Figure V.1, a laser beam is
brought to its diffraction limited focus within a particular probe volume using a high-aperture
objective lens. A pinhole (typically 50-100 μm in diameter) can also be placed at the interface
with the sample, rejecting any light this remains out of focus. In conjunction with diffractive
manipulation of the beam, this allows for approximately
cylindrical observation volumes of 0.5-1.0 fl (~0.5 μm in
diameter and ~1.0 μm in height).
As labeled molecules enter the detection volume, the
red-shifted photons emitted by the excited fluorophores are
focused through the same pinhole and objective lens before
being reflected by a dichroic mirror into the detection
apparatus. Here the beam is divided equally between two
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Figure V.1 A typical confocal
microscopy setup, adapted from
Lundquist (2008).
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avalanche photodiodes by a beam splitter. If multiple emissions wavelengths are present,
dichroic mirrors can be utilize for color isolation. Alternatively, individual wavelengths within
the beam can be separated by prisms and focused onto characteristic regions of a charge-coupled
device (CCD) detector. In this setup, both the intensity and position of the light would be
recorded, allowing simple differentiation among many distinct fluorophores.

V.2 High-Multiplex Confocal Microscopy
For applications like SMRT sequencing that require spatial multiplexing, scanning
confocal microscopy has been the standard measurement technique. This method is proven and
well understood, but the frame rate is limited by the period of the scanning mechanism and by
design, it cannot provide continuous observation of any single site. Our throughput requirements,
however, demand the simultaneous monitoring of over 250,000 individual waveguides,
completely ruling out scanning microscopy as a viable detection method. Rather, we will make
use of recent advances in high-multiplex confocal microscopy to facilitate the collection of realtime, high-sensitivity fluorescence data60.
The greatest single innovation in this field is the use of holographic phase masks (HPMs)
to split a single excitation laser beam into an array of sub-beams at the same wavelength. These
HPMs can be customized to generate almost any pattern of excitation radiation and almost any
wavelength, and are thus readily adaptable to any number of sample volume configurations.
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In consideration of the multiple excitation
wavelengths required by the four fluorophores in
use, multiple arrays from different sources could
be combined using relay lenses and dichroic
mirrors into a common illumination plane before
being directed by the objective lens onto the
sample. The emitted light is then collected through
the same objective, deflected 90 degrees, split, and
focused onto two single photon sensitive EMCCD
chips. Previous applications of this CCD-based

Figure V.2 High-multiplex confocal microscopy
setup. The images in the bottom right illustrate
the spatial wavelength identification method.
Reproduced from Lundquist (2008).

technique have utilized prism assemblies to disperse the emitted light over several CCD pixels,
providing continuous color separation for the spatial identification of wavelength.
In order to obtain high-resolution spectra, however, 15 pixels would be required for each
ZMW, severely limiting the observational capacity of each EMCCD. Moreover, the entire
purpose of a ZMW is to attenuate background noise by reducing observation volume. This
renders confocal techniques, even those which support simultaneous spatial multiplexing,
unnecessarily complex and expensive.

V.3 Two-Color Wide Field Microscopy
Our detection process will utilize some of the simplest illumination and observation
methods, relying almost entirely on the properties of the ZMW and the back-illuminated
58

Optical Detection

EMCCD to facilitate high-quality signal acquisition. Excitation energy will not be provided by
laser, but by a mercury arc lamp whose output will be split, wavelength filtered, then recombined
onto the ZMW array. This requires no complicated optics, such as phase masks, while still
providing uniform illumination. A high numerical aperture, low-distortion objective will enable
the observation of the entire ZMW array simultaneously with the precision necessary to map
each waveguide to a single EMCCD pixel. The EMCCDs themselves are mounted in a manual
precision dual-port camera adapter for reliable CCD-to-chip alignment.
The fluorophore detection technique has also been designed to be optically simple and
equipment efficient. Rather than devoting 15 pixels to each ZMW for spatial identification, we
devote only two. Proper identification is performed by recording separate wavelength spectra on
each pixel, and taking the ratio of intensities between the two. Physically, this is accomplished
by using a dichroic mirror in the beam splitter at the core of the precision alignment adapter.
Wavelengths higher than the cutoff are reflected to one camera, while the rest pass through to the
second. Since both CCDs are aligned to the same waveguide array with 1-to-1 mapping, each
pair of pixels will correspond to a single ZMW, and record the progress of a single polymerase
molecule. The ratio of emissions intensities detected on each CCD will determine which
fluorophore was excited, thereby identifying the nucleotide just added to the sequence. Despite
doubling the number of cameras required, this method yields a 15-fold reduction in the number
of pixels needed to identify a fluorophores, thereby reducing the overall detection equipment
requirements 7.5-fold.
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In order to guarantee that the individual peaks corresponding to the presence of a specific
fluorophore, and thus a specific base, could be detected using the dual camera system, a read
error analysis was performed using the Monte Carlo statistical method on the specific
fluorophore peaks. Monte Carlo measures the independent fluctuation of multiple variables that
affect a function. This is a perfect statistical method for analyzing the variation of light intensity
read by both cameras.
As described earlier, the method used to determine the identity of the fluorophore
emitting the light involves comparing the intensities hitting each camera. Since each fluorescent
molecule has an individual light intensity distribution over a range of wavelengths, creating a
cutoff wavelength for each camera divides the intensity readings between two cameras. With the
individuality of each intensity distribution in mind, then the ratio of intensities for each peak

Figure V.3 Intensity Distribution of Four Fluorophores. The figure shows the intensity distributions over
a range of wavelengths for fluorophores coupled with (1) dATP, (2) dTTP, (3) dGTP, and (4) dCTP. The
camera wavelength ranges split the peaks at 638 nm, with camera 1 capturing the majority of dATP and
dTTP, and camera 2 capturing the majority of the dCTP and dGTP intensities.
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should be molecule specific. That is Rpeak for each fluorescently tagged dNTP should be specific
so that identification of each base is possible. Rpeak is given by:
=

Equation V.1

where Ic2 is the intensity reading for camera 2 and Ic1 is the intensity reading for camera 2. Using
the intensity distributions in Figure V.3, the areas under each peak can be found. The
wavelength cutoff between camera 1 and camera 2 was chosen to be at 638nm wavelength, at the
intersection of the intensity distributions for peaks 2 and 3. This allows for relatively balanced
intensity readings for each camera. Using ImageJ software, the area under the intensity curve for
each peak is measured over the wavelength ranges for each camera, giving Ic1 and Ic2 readings.

Figure V.4 Intensity Division of dTTP Fluorophore for Cameras 1 and 2. The figure above shows the normalized
peak for the dTTP attached fluorophore. The line down the middle represents the wavelength cutoff for
cameras 1 and 2, with camera 1 on the left and camera 2 on the right. The area under the peak is measured for
the wavelength coverage of each camera using ImageJ software. The same process was repeated for the other
three fluorophores.
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Using these values, the ratio of intensity readings of camera 1 vs. camera 2 can be calculated.
For example, Ic1 and Ic2 for dTTP were found to be 28178 and 1801, respectively, giving an
intensity ratio of Rpeak=0.063915.
= 1801 28178 = 0.0639145

Equation V.2

In order to estimate the deviation from this value, a Monte Carlo statistical analysis was
performed using MATLAB. The Monte Carlo method requires knowledge of the standard
deviation of the peak intensities captured by each camera. This is a difficult proposition, since
Invitrogen does not provide data on the variation of the intensity vs. wavelength variation for
their Alexa-Fluor dyes. An alternative method for finding the standard deviation is possible
using brightness deviation values (See Table V.1)20. Since brightness correlates with light
intensity, we assume that the standard deviation for the brightness also directly correlates with
the standard deviation for each peak area of the normalized intensity curves. Therefore it is
possible to find the standard deviation percentage for each fluorophore peak.
%=

%

ℎ

ℎ

.

= 39 2781 × 100 = 1.4024%
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As shown above, the standard deviation percentage for the dTTP intensity is 1.4024%.
By multiplying the standard deviation percentage by the Ici values, a standard deviation for the
intensity readings of each fluorophore for each camera can be estimated.
1

.

=

.

.% ×

= 395.1607

Equation V.5

The standard deviation readings for each peak and for each camera are shown in Table
V.1 below. These standard deviations can then be used to carry out a Monte Carlo simulation
using MATLAB. The simulation examines the distribution of Rpeak using Equation V.1 and the
standard deviations found for Ic1 and Ic2.

The normal distributions for Ic1 and Ic2 are first

generated in MATLAB using the following code:
ca_cb= (randn(n,1)*std)+mean;

where std is the standard deviation of the intensities found earlier, n is the number of iterations,
and mean is the average value of the intensity per camera, or in this case Ici. This process is
performed for the intensity distribution of each peak for every camera.

The Monte Carlo

simulation is carried out using the distribution generated for each camera for a specific peak.
peak2 = c2_2./c1_2;

where the above code is analogous to Equation V.1 for the dTTP intensity distribution. The
process is repeated for dATP, dGTP, and dCTP. Once the distribution of each peak ratio is
generated, the next step is to calculate the medians and the standard distributions found for each
fluorophore. These are listed in Table V.1 on the previous page. By plotting the histograms of
each fluorophore camera intensity ratio, it is evident that there is no overlap between the ratios
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for each fluorophore peak. It is clear that by using the dual camera peak identification setup
would not produce base mismatches due to overlap of Rpeak values.

The complete MATLAB

code for the simulation is found in Appendix E.6.

dATP

dTTP

dGTP

dCTP

Peak

1

2

3

4

Brightness

6,446

2,781

4,865

2,691

Brightness Std. Dev.

109

39

92

41

Brightness Rel Std Dev (%)

0.01691

0.014024

0.018911

0.015236

Ic1

24,198

18,178

548

110

Cam 1 Std. Dev.

409.181

385.160

10.363

1.675

Ic2

226

1,801

25,175

31,303

Cam 2 Std. Dev.

3.822

25.257

476.074

476.932

Rpeak

0.0093

0.0639

45.9398

284.5727

Ratio Std. Dev.

6.36 x 10-5

3.65 x 10-4

0.352

1.76

Table V.1 Data for Dual Camera Error Analysis. The following table shows data required for performing a
Monte Carlo simulation demonstrating that the reliability of using a two camera system in order to detect 4
different fluorescent molecules. Ic1, and Ic2, are values obtained using ImageJ for the areas underneath the
intensity distribution curves from Fig. IV.3. The areas are measured for the intensities for the wavelength
range of each camera, set at 638 nm. The Camera standard deviation columns are obtained by multiplying
the Standard deviation % column with the Ic1 and Ic2 columns. The Ratio Standard Deviation column is the
standard deviation calculated using a Monte Carlo simulation in MATLAB.
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Figure V.5 The above image shows histograms produced for the distribution of log(Rpeak)values for dATP, dTTP, dGTP,
and dCTP using the Monte Carlo method in MATLAB. The red, green, blue, and magenta curves are the histograms for
dATP, dTTP, dGTP, and dCTP, respectively. It is clear that the lack of overlap between each Rpeak value demonstrates
that the two camera system should not result in base mismatches due to Rpeak value overlap.
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V.4 Fluorescence Detection and Signal to Noise
Electron Multiplying Charge Coupled Devices (EMCCDs) present a critical component
in the design for high throughput genome sequencing. EMCCDs are capable of capturing single
photon events at high read-out speeds. The chip uses the principles of impact ionization in order
to register and multiply the presence of an electron. In order to deal with issues of background
noise, EMCCDs employ an Electron Multiplying (EM) solid state register that amplify the signal
from the electrons before passing through the output amplifier. The extra register at the end of
the first register allows for the amplification of the signal without requiring an image intensifier,
which would add noise to the image, lowering the camera performance. This elimination of
background noise is critical when dealing with light signals from an individual molecule. This
design is perfect for use in conjunction with the waveguide containing the biochemical
reaction.61
The light emitted from each waveguide is lined up
with the individual EMCCD pixels using a mechanical stage.
The EMCCD desired for the setup is the iXon+ DU-897E
from Andor. The camera provides a 512x512 resolution chip
Figure V.6 Andor iXon+ DU-897

with individual pixels that are 16µm in size. This dedicates a EMCCD Camera (Andor Tech.
PLC, Belfast, Northern Ireland)

single pixel to manage the light from an individual
waveguide.62
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An important aspect to photodetection is the quantum efficiency (QE) of the CCD. The
QE is defined as the percentage of photons that are actually detected and then transmitted as
electrons by the photodetector. The QE of a camera is important in determining the signal to
noise when detecting the light used. In general the higher that the QE of the camera being used
is, the better the better the quality of the reading will be.
One of the most important determinants of the QE of an
EMCCD is the wavelength of the light that is detected.
For the purpose of the sequencing process, wavelengths

Figure V.7 Wavelength dependency of QE of
24
the Andor iXon+ Du-897 EMCCD camera.

between the range of 500nm and 700nm need to be
detected by the EMCCD.

According to the QE vs

wavelength curves generated by Andor (see Figure V.7) , the iXon+ 897 ranges in QE from 0.95
to 0.98 within the desired wavelength range. This is as close to an ideal QE as possible with the
current technology allows.24
Another important quality of the EMCCD is its readout speed. The camera should be
able to detect the light produced from the reaction faster than the actual reaction occurs. That is
to say the frame rate of the camera should be significantly faster than the excitation period of an
individual fluorophore. This is important, since the fluorophore is excited while it is being
attached to the DNA template. Once the next base is added, the fluorophore is no longer
detected and the next signal has to be dealt with. Therefore in order to prevent base readings
from blurring together, the frame rate of the camera should be faster than the nucleotide addition
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rate for the phi 29 polymerase. With a frame rate of 31 frames per second (See Appendix D.3)
the iXon+ 897 easily surpasses the maximum dNTP addiction rate of 4 bps.
In order to successfully identify the presence of a fluorescent molecule, it is important to
have a favorable signal to noise ratio. Signal to noise ratio simply describes the relevant signal
from the fluorophore as compared to the extraneous information. This extraneous information
can be due to several different factors, including background noise and shot noise. Background
noise includes any signal coming from ambient sources. Shot noise occurs due to statistical
fluctuations of finite number of particles detected as a result of random arrival time. The number
of photons collected by the detector can be described as a Poisson distribution and the noise can
be described as the standard deviation of that or the square root of the average number of
photons collected. Therefore, a simplified version of the signal to noise ratio can be modeled by:
=

=

Equation V.1

where np is the average number of photons detected.20 From this equation, it is easy to see that
as the number of photons detected increase, the signal to noise ratio increases. When accounting
for noise from the signal transmission in the light detector and for the baseline noise read or the
background read, the relationship becomes:

=

2
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where bkg is the background noise, and √2 is a correction for the noise from the EMCCD

camera.20 Considering all of these conditions, a signal to noise ratio near 100 would be favorable
for a reliable read. Using these parameters, Eid and colleagues tested a waveguide containing
phi29 polymerase and fluorophore labeled dNTPs. The lowest signal to noise ratio found was
356 for the dTTP fluorophore. This number is well above the desired ratio of 100, meaning that
using the same fluorophores, the light signal can be reliably detected. The experiment also
proved that a large number of photons are emitted by the fluorophores, on the order of 250000,
making the background noise inconsequential.20
In order to account for the potential difference in EMCCD cameras used in the
experiment, one can consider the quantum efficiency (QE) of the camera.

=

∙

∙

+

Equation V.3

where nn refers to the sensor noise.63 Since, np is so high, the sensor noise is not as important, it
can be ignored. Using the QE of around 0.98 for the camera in our experiment
= 0.99

Equation V.4

which for a large number of photons emitted by the fluorophores gives a favorable signal to
noise ratio estimation.24
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V.5 Conclusions
By using two iXon+897 EMCCD cameras along with a high-multiplex confocal
microscopy setup per station, the high throughput imaging necessary to view the
throughput of the biochemical reaction on the chip is possible. After analysis of the dual
camera setup, it is clear that it is possible to view and differentiate the four fluorophores in
the ZMW by dedicating a total of two pixels per waveguide, maximizing the throughput of
the setup. Upon considering the signal to noise conditions from the setup, the use of
iXon+897 EMCCD in conjunction with the fluorophores used to tag the DNA, the high signal
to noise ratio proves to be favorable for quality performance viewing of the reaction taking
place, and a subsequently lower error rate in reading the DNA sequence.
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Genome Assembly

The field of bioinformatics encompasses the development of databases, algorithms, and
other computational techniques for the indexing and analysis of biological information, including
DNA sequences.64 This unique discipline lies at the intersection of computer science, biology,
mathematics, and medicine, providing the very tools required to compile and analyze genomic
data. The functionality provided is similarly diverse, ranging from protein modeling to gene
mapping, and even to determining the evolutionary history of a particular organism. Indeed,
without these advanced capabilities, a full-genome sequence would be of little practical value, as
its relevant information content could not be decoded.
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This chapter, however, will focus exclusively on the aspect of bioinformatics that is most
relevant to PennBio’s business plan – genome assembly. With a sample of some 27 million
fragments of random length and sequence being generated during the observation of the SMRT
chip, this final step in genome “production” is perhaps the most difficult and resource-intensive.
Many different assembly techniques exist, all varying in experimental fragment length,
knowledge of the target sequence, and specific alignment algorithms.
The following discussion of the Human Genome Project and Celera Genomics illustrates
quite clearly the rapid, almost quantum advances that have been made in genome reassembly in
the last two decades, and provide important background and precedent for the PennBio method.
Further detail will then be given regarding the specific considerations and calculations that were
involved in the development of a reliable, efficient assembly procedure. Finally, the results of an
original Monte Carlo assembly simulation will be discussed with respect to its usefulness as a
model validation tool, and as a means of predicting the computational resources necessary to
meet PennBio’s throughput goals.

VI.1 The Human Genome Project
The early whole-genome sequencing ventures, including the Human Genome Project
(HGP, 1990-2003), took what is now considered a brute force approach to sequencing
determination65. The complete human genome was fragmented into long strings, some 150 kbp
in length, and distributed to laboratories around the world for analysis. These genome fragments
were sequenced in a processive manner, starting at one end and proceeding to the other, one base
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position at a time, before the completed fragments were mapped to chromosomes and
reassembled into a single consensus genome. This method is referred to as the “hierarchical
shotgun” approach, and was selected by the HGP principally for its ability to accurately map
repeat-rich sequences, and also because it allowed the project workload to be shared across
several analysis sites. In the Nature article announcing the endeavor’s completion, the authors
insist that “the advantages of this more conservative approach outweighed the additional cost, if
any.”66
During its thirteen year timeframe, the HGP was the focus of over 20 public molecular
biology laboratories and approximately $3 billion is public funding. Its contributions to genetic
science, particularly as an ardent proponent of the human genome as public-domain information,
are indisputable, but many have questioned the efficiency of their sequencing method. In fact,
just eight years into the Project, a private biotechnology firm – Celera Genomics – launched a
parallel human genome sequencing venture based on the whole-genome shotgun (WGS)
technique.

VI.2 Whole-Genome Shotgun Sequencing
Whole-genome shotgun sequencing is distinguished from the hierarchical method by its
short read lengths. In contrast to the 150 kbp fragments used by the publicly-funded effort,
Celera generated fragments a mere 550 bp in length67. The entire fragment library was then
aligned simultaneously to create a full consensus genome, rather than first producing long
intermediate sequences. By 2001, Celera had caught up to the public HGP, and the two
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competitors published their draft genomes within two months of each other. The price of
Celera’s finalized sequence, however, was reported to be $300 million – a tenth of the public
funding required. As striking as this cost differential is, it must be considered in context. Celera’s
project had, on its first day, free and unrestricted access to the public project’s progress, which
was updated daily. The extant sequence information made the mapping of short fragments much
less uncertain than the initial de novo assembly case, and permitted the use of less rigorous
assembly techniques68. It is difficult to say whether the approach would have been as successful
without a template, incomplete though it was. Indeed, the scientists on the public side may have
been right to choose the more painstakingly accurate method.
But regardless of what could have been, Celera’s success confirmed that WGS
sequencing was a viable and time-efficient alternative to the older techniques. Modern
sequencing operations are nearly unanimous in their acceptance of this approach, and it has
benefitted considerably from advances in computing power and assembly algorithms.

Figure VI.1 A graphical comparison of the hierarchical (left) and whole-genome
shotgun (right) sequencing methods. Reproduced from Mihai (2004).
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VI.3 The PennBio Strategy
PennBio’s reassembly strategy combines the sensitivity of WGS with the public-domain
human genome sequence in a process often called comparative genome assembly65. As in the
classic technique, customer genomes are randomly fragmented into 2000 bp lengths, but rather
than being aligned to each other to produce a consensus sequence, each fragment is mapped to
the available genome. Given that individual sequences differ by one base in everything thousand,
on average, and the polymerase-related error rate is extraordinarily low modern alignment
algorithms can execute the mapping with a success rate of nearly 100%, and in a fraction of the
time and computational complexity required by de novo assembly46.
In this way, PennBio provides its customers with the most sophisticated of modern
analysis technique, resting on the shoulders of nearly two decades of human genomic study.
Exceptional accuracy, not only in identifying known SNPs, but at every base position is what
makes each sequence an essential tool in the most advanced molecular diagnosis both today, and
in the future as our medical understanding of the genome continues to grow. At the same time,
low cost and unprecedented throughput for bring this indispensible resource to the average
customer for the first time.

VI.4 The Coverage Problem
The most significant shortcoming of the shotgun method is its dependence on an
overgeneration of information, i.e., the requirement that the total length sequenced is several
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times longer than the target genome, itself69. With no such redundancy, the random nature of the
synthesis reaction would certainly yield gaps in the final genome. But as the total length
sequenced increases, the probability of missing any particular base position decreases. The
relationship follows a binomial distribution:

n
Pr( K = k ) =   p k (1 − p)n −k
k

Equation VI.1

where K is a random variable for the number of successes, k is a realization of this variable, n is
the number of trials performed, and p is the probability of success for each trial. Since the
number of successes is typically specified by the requirements of the reassembly algorithm, an
alternative formulation of this distribution – the negative binomial – is more useful. This
expresses the probability, f(n), that k successes will be achieved in n trials:

 n −1  k
n−k
f ( n) = 
 p (1 − p)
n
k
−



Equation VI.2

Given a particular base position, a success is achieved if a sequenced fragment exists containing
that base, under the assumption that it can be properly positioned by a reassembly routine.
Defined more rigorously, a success is achieved if the polymerase under observation has at any
point added a nucleotide at that particular position, generating a measureable signal, which was
then translated into a character in a random fragment which can be accurately positioned in the
final genome. Each of these steps in the single-position sequencing operation has a likelihood of
failure, and contributes to the determination of p. Therefore, each of these processes underwent
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individual statistical modeling in order to generate a final estimate for the redundancy required
for complete coverage. The following analysis is performed at the single base position level.
VI.4.1 Probability that the Polymerase Reached the Base Position
If a certain base is to be sequenced the polymerase must, at very least, physically arrive at
that particular position. Since polymerization is unidirectional, the probability that this
requirement is satisfied can be divided into two sub-probabilities: that the polymerase attaches to
the template strand before a given position, and that it does not release the template before
reaching it.
Phi29, and all DNA polymerases, will only bind to double stranded DNA. Since our
templates are necessarily single-stranded, short lengths of primer ssDNA are annealed to it,
providing the enzyme with attachment points. Template priming in this design is accomplished
by means of random-sequence six-base fragments of ssDNA (hexamers). These are demonstrated
to bind to the target ssDNA genome fragments randomly, and since polymerization can only
begin where a primer is bound, the actual sequenced strings will, themselves, have a random
distribution that is both a function of fragment length and the relative primer and target
compositions.
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Random primer binding is modeled by the Poisson distribution, with a rate parameter, λ,
and a total nucleotide distance, x (often called exposure)70:

Pr( R = r ) =

(λ x ) r e − ( λ x )
r!

Equation VI.3

This equation expresses the probability of observing r primer binding events over a length of x
bases of ssDNA. In this case, λ is defined as the molar ratio primer to template, which is
equivalent to the ratio of the number of primer hexamers, nprimers, template fragments, nfrag:

λ=

n primers
n frag

=

n primers
lgenome

Equation VI.4

µ frag

where lgenome is the length of the human genome (3 gbp) and µfrag is the mean length of a
fragment (2 kbp). Taking the genome and mean fragment lengths as constants, this parameter can
be optimized by varying the number of primer molecules present for a given coverage
multiplicity.
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Figure VI.2 The optimal priming strategy. A less aggressive approach reduces
primer-excision lags and conserves the relatively expensive reagent (blue).

Realistically, there will be a large excess of template DNA in the reaction mixture.
Therefore, low concentrations of unprimed template are not expected to have a significant effect
on the overall sequencing rate. It becomes more important to consider the number of primers per
fragment, since the polymerase must pause to remove these if they are encountered during
polymerization, causing a noticeable delay. In this case, the acceptable proportion of unprimed
fragments was set at 10-1, yielding a rate parameter of 2.3 (equal to the mean), which represents a
6-fold decrease in the amount of random primer required for each sequencing reaction without
sacrificing performance.
Assuming priming is optimal and the enzyme has begun to sequence its template, there is
a probability of it detaching before polymerization is complete. This probability increases with
total distance traveled along the template – a characteristic distance that varies greatly from
enzyme to enzyme. Indeed, phi29 was selected in part due to its capacity for very long read
lengths, with a reported mean value of 70 kbp. Like primer binding, the occurrence of a release is
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a Poisson event. Therefore, the distance before the first release can be modeled by the
cumulative gamma distribution, with a mean of 70,000 and shape parameter, k, equal to 1. In this
special case, the gamma distribution is equivalent to the exponential distribution with the rate
parameter, λ, equal to 1/70,000:

Pr( X ≤ x ) = 1 − e − λ x

Equation VI.5

where X is a random variable denoting the number of bases traveled, x is a realization of X, and
Pr(X ≤ x) is the probability of a release occurring at or before x. For a mean fragment length of
2000 bp, the probability of release at or before the terminal base was 2.8% – fairly low, even
assuming the polymerase covered the full length of the fragment.
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Figure VI.3 The probability of incomplete
polymerization with respect to fragment length.
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VI.4.2 Probability of Misidentifying
identifying a Nucleotide
While phi29 is capable of remarkabl
remarkablyy high fidelity, the system’s optical limitations result
in an error rate of 1 in every 500 nucleotides. Like primer binding, the total number of errors per
fragment, R, over a distance, x,, is Poisson distributed with an expected rate of λ71. Therefore, for
a sequenced string of 1000 bp, the mean number of errors is 9, with a 99% confidence interval of
[0,22].
VI.4.3
.3 The Complete Negative Binomial Estimate
Given the parameters derived above, the probability of success at any particular bbase
position is 0.963. Unambiguous nucleotide assignment requires three successful trials per
position (k = 3),
), and an incomplete coverage rate of 1 per 100,000 bases sequenced.. Evaluation
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Figure VI.4 Negative binomial estimate of required coverage multiplicity. Points within the shaded
area satisfy by the coverage and error rate specifications, and are considered acceptable.
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This multiplicity value is critical to the calculation of throughput, which in turn is central
to PennBio’s business model. With so many random events involved in DNA sequencing, further
validation of these estimates is certainly warranted. A Monte Carlo MATLAB program was
developed to simulate the phi29-mediated polymerization process – allowing the manipulation of
release rate, various error rates, and target genome length – followed by an algorithm designed to
reassemble the sequenced fragments and assess any errors made. While the realistic genome
generation routine is purely for purposes of model validation, the latter reassembly portion bears
remarkable similarity to alignment software in use today, and could be used to reassemble
personal genomes during operation.
The purpose of this section is not to delve too deeply into the programming behind this
simulation, but rather to illustrate the rigor PennBio’s process evaluation, and to provide
repeatable, statistically sound evidence of the project’s practical viability.

VI.5 Simulation Overview
VI.5.1 Genome Generation, Fragmentation, and Polymerization

A random genome of specified length is generated by the randseq function and stored as
the “consensus” genome – the simulation-level equivalent of the HGP sequence. Singlenucleotide polymorphisms (SNPs) are then inserted at exponentially distributed intervals to
create the “actual” genome sequence of interest – the customer genome. This “actual” genome is
sonicated into fragments of normally distributed lengths about a mean of 1000 bp, which are fed
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to a phi29 polymerase. As it polymerizes each fragment, the enzyme introduces errors at
exponentially distributed intervals. Deletions are also inserted to reflect possible detection faults,
and to evaluate the robustness of the alignment algorithm to phase shifts.
This polymerization protocol is repeated a specified number of times, randomly storing
or deleting fragments as they are created according to the output of a uniform random number
generator, with a probability of fragment storage of 1%. Fragment generation ceases when the
desired coverage multiplicity is achieved, simulating the randomness with which the polymerase
sequences the excess of DNA fragments present in the reaction mixture and allowing evaluation
of the previous redundancy estimate.
VI.5.2 Reassembly of Random Fragments

These fragments are then locally aligned to the “consensus” genome by the built-in
Smith-Waterman algorithm (swalign function), recording the starting point of the alignment and
fragment length. These data are used to keep a running tally of nucleotide “votes” at each
position in the genome. After all fragments are aligned in this way, the votes are counted, and a
value of A, C, T, G, or X is assigned to each position, generating the “final” genome, with X
signifying ‘blank’ or ‘inconclusive.’
A short script at the end of the program then compares the “final” genome to the “actual”
starting genome and generates an error rate. The application of various sensitivity analysis scripts
allows the examination of the effects of various computational and biological parameters on the
error rate, which must be less than 1 in 100,000 bases.
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VI.6 Initial Simulation Results
Due to memory restrictions, the initial simulations were carried out on genomes with
lengths of less than 20.000 kbp, with 10.000 kbp being the most common length used. The final
error rates of these first simulations were on the order of 10-3 – well above the specified
threshold to 10-5. Many of these resulted from a failure of the alignment algorithm to correctly
recognize deletions within the fragments, so the swalign subroutine was then modified by
varying the penalties for opening gaps in the sequence, and the penalties for extending these
gaps. This improved the mean error rate to 10-4, which seemed to be independent of any further
adjustments to program parameters.
Subsequent examination of the particular error locations revealed that they were caused
by the concurrence of insufficient coverage (only two bases per position) and ambiguous base
definition (a tie vote – the two bases were not identical). This was inconsistent with our
statistical coverage predictions. The program responded to such situations by designating that
base ‘X’ as instructed, eventually resulting in an error in the final alignment. Two options existed
in correcting this unanticipated deficiency – either establishing a protocol by which the HGP
genome would resolve the ambiguity, or increasing the multiplicity.
Initially, the first course of action appeared more attractive, as it required little adjustment
to the physical and temporal requirements of the sequencing system. Moreover, since the
sequencing technique is based on knowledge of the human consensus sequences, an extremely
accurate tie breaker was readily available. Deferring to the consensus sequence in the cases of
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ambiguous base assignment was expected to fail if and only if the base in question was a SNP. In
this scenario, completely random assignment would actually be more reliable, as by definition of
“SNP,” it would not agree with the known sequence. Therefore, the expected error rate was a
product of the SNP frequency (10-3) and the frequency of insufficient, ambiguous coverage (104

), which was on the order of 10-7 errors per base sequenced.
While this seems acceptably low, and is certainly below the threshold of 10-5, it is

nonetheless unsatisfying. First, the probability must be put into perspective, remembering that a
human genome is approximately 3 gbp long. We would therefore expect to misidentify an
average of 30 SNPs on each genome sequenced. Second, and perhaps even more importantly,
SNPs are considerably more significant in the molecular diagnosis of diseases. This is why most
sequencing technologies, until now, have relied on SNP screening – providing only the most
effective data at a reasonable price. To allow even 30 SNPs per genome to be improperly
analyzed would dramatically decrease our product’s diagnostic power, and could make it
difficult to displace the SNP screening assays already in common use.
Instead, the decision was made to increase coverage multiplicity until the average error
rate was below 1.00 x 10-5 errors per genome. As the simulation is constructed, this was a very
simple operation, merely requiring the manipulation of a single input constant (mult) within the
sensitivity analysis loop. Values between 8.00 and 11.00 were examined with a step size of 0.25
before concluding that a multiplicity of 9.00 proved the optimal balance between error rate and
physical equipment limitations.
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VI.7 Final Error Rate Calculations
Satisfied with the program’s performance, and with the biological accuracy of the input
parameters, the final objective of this simulation was to determine the expected error rate in each
sequenced genome. To this end, a large sample was generated by simulation iteration. The inputs
were fixed, and are given in Table VI.1.A. The iteration routine collected final error rates from n
= 660 independent trials using 20.000 kbp target genomes. These were then consolidated into a
single table of count, given in Table VI.1.B, which shows the number of trials that were
completed with a certain number or errors.

B. Results

A. Inputs

Value

Errors Per Trial

Count

Genome Length

20 kbp

0

593

Fragment Length

1 kbp

1

48

Multiplicity

9-fold

2

14

SNP Rate

1/1000

3

5

Error Rate

1/500

4

0

Deletion Rate

1/500

5

0

Parameter

Table VI.1 Input parameters in the determination of error rate (A). The simulation results, as count data (B).

Like many of the molecular-level processes described in previous sections, instances of
disagreement between the final genome and the target genome were assumed to be rare and
Poisson distributed. In order to test this hypothesis, the index of dispersion was computed for this
data set using the formula:
D=

σ 2 0.207
=
= 1.502
µ
0.138
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where σ2 is the sample variance, and µ is mean number of errors per 20.0 kbp trial. In the case of
the Poisson distribution, the mean and variance are equal, and D = 1. When the index of
dispersion is greater than one, the events are said to be overdispersed, and are better
characterized by a negative binominal distribution. This adds a dispersion parameter, α, to the
calculation, and better accounts for unobserved heterogeneity in sample. In fact, the Poisson
distribution is simply a special case of the negative binomial with α = 0. If this can be shown to
be the case with the sample data, a Possion approximation would be valid.
This possibility was evaluated by performing a negative binomial regression nbreg on the
sample (Stata 10.2), which estimates, among other things, the dispersion parameter. For this
sample, the reported value was α = 0.099 with a standard error of 0.067. A z-test of the
hypothesis that α = 0, however, returned a p-value of 0.138. We therefore fail to reject the null
hypothesis, and are justified in our use of the Poisson distribution in fitting the data.
The maximum-likelihood estimator of the error rate is given by the formula:
n

λˆMLE =

∑R
i =1

i

Equation VI.7

n

This is equivalent to the arithmetic mean of the number of errors, R, over n independent trials.
The error rate for the actual sample is therefore given by:
λˆMLE ,avg =

91 errors
= 6.89 × 10 −6 errors/bp
(660 trials) ⋅ (20, 000 bp/trial)
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Upper (UL) and lower limits (LL) of the confidence interval can then be constructed about this
value using the chi-square distribution72:

LL =
UL =

χ 2(2 R +1),(1−α

2)

2 ⋅ (20, 000 ⋅ navg )

Equations VI.9, 10

χ 22R ,α 2
2 ⋅ (20,000 ⋅ navg )

where R is the total number of errors observed, α is the significance level, and (20,000∙n)
represents the sample in total bases. Several possible confidence intervals are given in Table
VI.2, and show that that only at α = 0.0001 (99.99% CI) does the upper limit cross the 10-5
threshold. This provides quantitative evidence that the probability of producing a genome with
an error rate higher than 10-5 is extremely, and acceptably, low under the specified biological
conditions.

95% CI
-6

Lower Limit

5.55 x 10

Upper Limit

8.46 x 10-6

99% CI
5.17 x 10

-6

8.98 x 10-6

99.9% CI

99.99% CI

-6

4.43 x 10-6

9.61 x 10-6

1.02 x 10-5

4.76 x 10

-6

Table VI.2 Confidence intervals for various values of α, centered about a mean of λavg = 6.89 x 10 .

As mentioned previously, reliable SNP identification is essential if current SNPscreening services are to be displaced by whole-genome sequencing. Indeed, if the error rate in
the most important segments of the genome were found to exceed the 10-5 threshold, the value of
average error rate would be meaningless. The code was therefore run for an additional n = 660
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iterations, this time with a new subroutine that tracked the SNP-specific error rate. The Poisson
rate parameter was calculated, using the formula state above, to be:
λˆMLE , SNP =

2 errors
= 7.56 × 10 −5 errors/SNP
26453 SNPs

Equation VI.11

Likewise, the upper and lower limits of the confidence intervals about this mean are:

LL =
UL =

χ 2(2 R+1),(1−α

2)

2 ⋅ (nSNPS )

Equations VI.12, 13

χ 22R,α 2
2 ⋅ (nSNPS )

Table VI.3 shows the confidence intervals for the SNP-specific error rate, which were
calculated using Equations VI.12 and VI.13. Unlike the average error rate, this parameter does
not, at first, appear to be below the error threshold. The discrepancy, however, arises from the
much smaller sample size. While the average error rate was calculated from 1.32 x 107 bp over
660 trials, only 26,453 SNPs were recorded in twice as many (1,320) trials. Given the confidence
intervals, however, it is clear that even for α = 0.05, we cannot reject the hypothesis that λSNP =
10-5. Judging from experience in calculating λavg, the mean will continue to fall as the sample size
increases.

95% CI

99% CI

99.9% CI

99.99% CI

Lower Limit

9.16 x 10-6

3.91 x 10-6

1.21 x 10-6

3.79 x 10-7

Upper Limit

2.73 x 10-4

3.51 x 10-4

4.56 x 10-4

5.56 x 10-4

Table VI.3 Means and 99.9% confidence intervals for the average and SNP-specific error rates.
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VI.8 Computing Time and Code Optimization

With the error rate under control, the practical issue of computing time required to
sequence a complete genome was addressed. As previously mentioned, memory was a limiting
factor in the choice of representative genome length. In addition to this restriction, the time
required to generate, fragment, and reassemble the 10.0 kbp genome was approximately 15
minutes. In a best case scenario where computing time scales linearly with target genome length
– a relationship that is, in fact quadratic – this translated into a 3 gbp sequencing time of 2.70 x
108 seconds, or about 8.65 years.
The physical computing specifications were inflexible, so code optimization became the
primary focus of attention. Preliminary alignment script analysis was carried out using the
MATLAB Profiler tool, which records and graphically displays the number of calls to each
function, and the total amount of time these calls represent. This revealed the alignment
algorithm itself (swalign) to be responsible for an overwhelming proportion of computing time
and memory usage. The Smith-Waterman algorithm, while very robust to any number of input
errors, is known to be very resource demanding73. Both the alignment time and memory
requirements scale by the product of the two sequence lengths74.

Given this non-linear

relationship, decreasing sequence length was expected to produce significant decreases in
processing time. These lengths were, however, fixed either by nature of by other practical
considerations. Instead, a hypothetical “short fragment” was created, allowing the alignment
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process to be divided into a fast position determination step, followed by a much more restricted
full-fragment alignment.
First, the beginning 10 bp (1%) of the fragment of interest were aligned to the full
consensus genome. This enabled the same positioning accuracy and repeatability as fullfragment alignment, but took a fraction of the time, as it reduced the memory requirements 100fold. The alignment starting point was then fed to a second swalign call which aligned the full
fragment to that particular section of the genome, once again dramatically reducing computing
time, despite adding extra steps. With this two-phase method is place, computing time for a 10.0
kbp genome decreased from 15 minutes to 15 seconds – a 60-fold reduction.
The code was further optimized according to the MATLAB standards outlined in
“Techniques for Improving Performance,” by replacing all non-essential cell arrays with
matrices, as MATLAB cannot accelerate for loops involving cell arrays75. Vectorization of all
remaining loops, where possible, also increased performance. Finally, the full script and certain
complex operations within it were converted to functions, allowing MATLAB to more
efficiently load them into memory before execution. Computing time was further reduced from
15 seconds to less than 5 seconds for a 10.0 kbp target genome at 9.00-fold multiplicity.
Target genomes up to 1.0 megabases in length were evaluated using the final program.
Computing time was approximately 3.1 hours for full assembly, with an average error rate of 8.5
errors per genome (n = 2). This is a significant improvement over the original 10.0 kbp targets,
and primarily serves to demonstrate the program’s much-improved memory utilization.
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(The complete simulation script, including subroutines, can be found in Appendix E.)

VI.9 Data Collection and Processing
Each sequencing station will be directly connected to a signal acquisition server in the
adjacent room. This unit will compare the frames of the two EMCCD cameras, identify the
fluorophores in each pixel, and convert the frame-based data into time-series data. This is then
translated into a nucleotide sequence by standard signal processing techniques and sent directly
to the genome reassembly server, rather than being stored. By not storing the fragments until a
complete set is generated, both sets of computers are utilized continuously, and no precious
processing time is wasted.
The genome reassembly servers are extraordinarily sophisticated, and were selected for
their exceptional memory efficiency and processing bandwidth. The sheer volume of data
passing through them in a single day demands such high-performance features. Local sequence
alignment speed, in particular, is particularly responsive to memory access rates and
multithreading capability. Indeed, successful reassembly is achieved only by minimizing the
time required by each individual task while maximizing the number of tasks that can be
performed simultaneous. Just as parallel operation is central to the overall process design, the
individual genome fragments are distributed to the many subunits of a multiple-core processor.
But with the complexity of modern computing systems, the result of this parallelization is not
always obvious, and deserved a more rigorous treatment.
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A preliminary assessment has been based on the properties of the reassembly simulation,
providing an estimate of the total computation required. Standardized performance benchmarks
were then used to more precisely define acceptable system specifications.

VI.10 Computational Demands
Using the finalized version of the assembly program described in Section VI.5, the
functional relationship between target genome length and alignment time was determined. Rather
than calculating total, single CPU processing time, however, the process was examined at the
single-fragment alignment level. That is, the time required to align a single 1.0 kbp fragment was
evaluated as a function of reference genome length. As shown in Figure VI.5, this effect is
linear, and has the form:
time = 0.00021 ⋅ genlength

R 2 = 0.9999

Equation VI.14

where time is in seconds, and genlength is the reference genome length in kilobases. In this case,
the intercept was set to zero, as the time required to create and manipulate empty matrices is
negligibly small with respect to any non-trivial alignment operations.
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Figure VI.5 The time required to align a single, 1 kbp fragment to a reference
2
genome of variable length. The line is a least-squares regression fit, with R = 0.9999.

These alignments were performed on an ordinary desktop computer with a 2.4 GHz Intel
Core 2 Duo 6600 processor and 2.0 GB RAM. Given the relatively low computational power of
this system, the total time required to align a 1.0 kbp fragment to a 3.0 gbp genome (3,000,000
kbp) was determined to be 630 seconds. Assuming a 3-fold increase in calculation speed could
be accomplished by translating the code into a more efficient language (such as C/C++), 210
seconds could, in practice, be realized. Properly scaled by the number of fragments, this
translates into a total genome reassembly time of 9.72 x 1010 seconds, or approximately 3,000
years at 9-fold coverage multiplicity (see Appendix A for detailed calculations). This value is
obviously and obstacle with a successful business model, and can only be overcome by way of
extraordinary computational resources, especially those that allow high-speed, massively-parallel
task execution.
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VI.11 Multi-Processor Speed-Up and Amdahl’s Law
The decrease in processing time afforded by the use of multiple processors (or multiple
processor cores) is fundamental to data-intensive computing strategies. In order to best
understand the benefit of a multiple-CPU approach, each computational step in the overall
sequencing process has been analyzed and separated into its “serial” and “parallelizable” parts.
Those designated “serial” must be performed in order, as each operation requires input from the
one before. Any tasks that can be accomplished independently are said to be “parallelizable,” and
to the extent that expenses allow, are simultaneously addressed by multiple processing units.
The multiplicative factor by which performance in increased when additional processors
are added is referred to as “speedup,” and can be calculated using Amdahl’s Law. This formula
expresses speedup, S, as a function of the number of processing units available, N, and the
fraction of the task that can be parallelized, P:

S=

1
(1 − P ) +

P
N

Equation VI.15

If 75% of an operation can be parallelized, for example, and it is divided among 4 processors, the
calculation speed is expected to increase 2.3 times. This is equivalent to saying that the time
required to complete the operation would decrease 2.3-fold.
The alignment routine itself is responsible for an overwhelming majority of the total
computing time. In fact, as the genome length becomes very large, the fraction of the computing
time required by this segment of the program goes to approaches unity. Fortunately, this process
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is almost 100% parallelizable, i.e., P ≈ 1. Each single-fragment alignment is completely
independent of the others, with the only interaction occurring in the final vote counting
procedure. Therefore, each computation-intensive alignment task could be delegated to a
separate processing unit. In this unusually clear-cut case, each additional processor is expected to
increase the overall processing speed by the same amount, and none of the diminishing returns
modeled by Amdahl’s law will be encountered.

VI.12 System Selection
In order to reduce the overall data processing time to a single day, a bank of IBM p560
Express servers will be utilized. These units are distinguished by remarkably high processor
bandwidths, large L1 and L2 caches, and most importantly, several independent processing
cores. They are also designed for practicality – being extraordinarily energy efficient and
compact. As shown in the previous section, the time required to align a 1.0 kbp fragment to
a full-length target genome on a typical office computer is:

time pc = 0.00021 ⋅ (3 × 10 6 kbp) = 630 s

Equation VI.16

Assuming the use of a lower-level programming language increases performance 3-fold, the
time required would be 210 seconds.
A single-core p560 server is at least 10,000 time faster than the computer used in
the above calculation, as measured by IBM’s commercial processor workload (CPW) index.
(The scale for this metric is normalized such that the processing speed of a midrange IBM
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System i server is defined to be equal to 1.00). The server model selected also has eight
independent CPU cores. Since the alignment routine is almost 100% parallelizable,
processing speed is increase by the factor:




1
S = lim 
=8

P →1
 (1 − P ) + P 
8


Equation VI.17

The maximum final genome assembly time at 9.00-fold multiplicity is therefore:

tserver =

9.00 ⋅ (210 s/frag) ⋅ (3, 000, 000 frag)
1


= (70,875 s) ⋅ 
 = 19.7 hr
10, 000 ⋅ (8 cores)
 3600 s/hr 

Equation VI.18

VI.13 Conclusions
While the assembly of a full human genome is, indeed, a complex undertaking, it has
been demonstrated not only to be feasible, but adherent to PennBio’s quality standards, and
consistent with single-day sequencing operations. The alignment program has been proven
effective and efficient, and has itself validated the probabilistic sequencing models developed.
Given sufficient computing resources – which are well within reason and budget – this program
can be run from start to finish in approximately 19.7 hours, as shown above, leaving a generous
margin for technical difficulties or delays. As a whole, the quantitative evidence provided in this
chapter has been fundamental to the practical evaluation of the PennBio sequencing approach,
and ultimately, the viability of its business model.
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VII. Financial Analysis
While the previous sections discussed the biochemical and technical aspects of this
project, it is imperative to analyze the financial aspect of the technology to determine whether
the project is financially feasible. If there is no existing market and no cash can be generated, no
investors would fund this project. Consequently, the technology would not be exposed to the
public. The financial analysis will show that the project is profitable. It will explain how that
decision was determined using NPV and MIRR analysis, and how those figures were calculated.
It is important to note, however, that these valuations are based on projected earnings, which in
turn, are based on several assumptions.
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The analysis begins with revenue projections based on the genomic throughput and price.
Because the entire model depends heavily on the revenue, a separate sensitivity analysis is done
on the genome price. Next, the total costs and depreciation are explained. Knowing these two
elements leads us to build an income statement. But because the income statement shows
earnings, and we want free cash, we want to adjust those earning figures into cash figures. To do
so, we then examine working capital and other cash affecting items.
Once we have the projected free cash flows, we can then value the company by
combining terminal value analysis and discounted cash flow analysis. Next, we do a rate of
return analysis for the investors. Because our project involves two rounds of investments from
two separate investors (series A and series B), this section becomes a little trickier than the
conventional analysis. To simplify the complications created by the multiple investments and
investors, we conduct an equity stake analysis. This will then complete our return of rate analysis
for the two groups of investors. Having completed all these explanations, we will put everything
together onto a single page spreadsheet.
Finally, we discuss multiple what-if scenarios and how that impacts the bottom line. The
scenario analysis will also involve a genome price sensitivity analysis to determine at which
point the entire project would lose money.
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VII.1 Market and Revenue Projection
The genome sequencing market is a relatively new and volatile market, originally tailored
to high net worth individuals. Currently, one existing company, Knome®, is charging $100,000
per client. Furthermore, due to technological improvement incentives like the Archon X Prize
competition, technology can be expected to improve. If that were the happen, costs would
significantly drop, and the price charged to clients would also fall dramatically. Little
information is known about sales volume, but even if it were known, the current economic
recession may render that figure irrelevant. Consequently, revenue projections are difficult to
nail down because genome sequencing is not a mature and predictable market.
For purposes of illustration, we will assume that our genome price is $10,000 for the next
several sections. Later on, we will conduct a sensitivity analysis on this price because the entire
financial analysis is heavily dependent on this figure. We also assume that 100% of our design
capacity is to sell the throughput of 3000 genomes per year: That is, our design capacity would
allow the company to gross $30MM per year.
The growth and development of the company fall into four stages: the research stage, the
scale up stage, the sales stage, and the terminal stage. During the research stage, scientists
develop a working prototype. There is no revenue and all the needed capital is provided by the
series A investor. Next, the scale up stage is where a working prototype has been developed, at
which point series B investors fund the rest of the necessary capital. New staff is added and there
is a step up increase after the company starts to make sales at a percentage of the design capacity.
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Ideally, this figure will be 50% of nominal capacity. After that, the sales stage is when the
company is fully functional and makes 100% of design capacity. Grown sufficiently, the
company makes the most money in this stage. Finally, the terminal stage is how the company
will end. A terminal value of the company will be calculated based on the prior free cash flow
projection. However, because there are multiple scenarios in the terminal stage, this will be
discussed in more detail in a later section.
Ideally, the research stage will take one year, the scale up stage another one year, the
sales stage three years, and the terminal stage will have one terminal value associated with it.
Because the genome sequencing market is a volatile, technology-related market, the company
will have a short lifetime.
The following table summarizes revenue projections.

Revenue Projections
Year
Stage Name
Design Capacity

Revenue

2010
30000
Research
0%

2011

2012

2013

2014

2015

Scale Up
50%

Sales
100%

Sales
100%

Sales
100%

Terminal
100%

$
-

$ 15,000.0

$ 30,000.0

$ 30,000.0

$ 30,000.0

Terminal Value

Table VII.1 Revenue projections for the following 5 years. ($ in thousands).

102

Financial Analysis

It should be noted that inflation is ignored from all financial analysis. The inflation
calculations are unnecessary and are only relevant in settings experiencing hyperinflation. In
fact, the Financial Accounting Standards Board determined in 1986 that inflation accounting is
unnecessary for financial statements.

VII.2 Costs, PPE, Depreciation
There are multiple, different costs associated with running PennBio. The costs can be
divided into four categories: research equipment purchase, research annual cost, sales equipment
purchase, and sales annual cost. The research equipment purchase includes all necessary
laboratory equipment for developing a working prototype. This includes microscopes,
computers, stations, EMCCD, etc. The research annual cost is how much the company spends
during the research stage. This mainly includes salary and rent. The sales equipment purchase is
the rest of the laboratory equipment purchased once a working prototype has been developed.
This equipment is used to scale up production. The sales annual cost is the annual burn rate of
the company when the company is able to generate revenue. This burn rate is significantly higher
than the previous burn rate: In addition to salary and rent, inventory costs, research and
development costs, and sales costs have been added. These cost figures are summarized in table
X.2.
The series A investors are paying for the research equipment purchase and one year’s
value of research annual cost as an initial fund. Because the research stage is the riskiest stage
(developing new technology), the series A investors are usually wealthy angel investors. In this
project, the series A investment comes to a total of $1.2MM.
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The series B investors come to invest once the risk of research has been reduced: only
when a working prototype has been developed, do the series B investors give funds to scale up
production. Their investment will be used for the sales equipment purchase, and 3 months worth
of salary, rent, and inventory, assuming the company will reach 50% of design capacity. The rest
of the salary, rent, and inventory will be funded by the revenue generated, but 3 months worth of
capital should be enough for the company to stay liquid. The series B investment comes to a total
of $3.5MM, which will be funded ideally one year after the series A investment, or whenever the
research stage is finished.
The labor costs for the research stage and the non-research stages differ. During the
research stage, the company must try to minimize all forms of cost, and salary is no exception.
Workers consist of a single secretary and four senior scientists, one of whom will also function
as a chief technical officer (CTO). In addition, because salary costs are large, and the series A
investor is trying to minimize his capital’s exposure to unnecessary risk, the scientists and series
A investor have come up with an agreement: the scientists will receive 70% of their ordinary
salary until a prototype is developed, in exchange for 10% of the company. Normally, in any
venture, the investor receives about 85% of the company to justify for risk, especially with
people inexperienced with entrepreneurship. But because this is a biotechnology company, and
biotech companies carry significantly higher risk, the series A investor feels he must receive
90% instead. Once a prototype has been developed, the scientists will receive their full salary.
The labor costs after the research stage are significantly higher: a CEO, junior scientists,
salespeople, and an IT specialist have been added.
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The rental costs for the research stage is lower than the non-research stages. Space is
minimized during prototype development but once it’s been developed, the space required for
sequencing and the molecular biology lab are expanded.
The inventory costs include only the SMRT chips and reagents. These costs depend on
the design capacity: at 100% of design capacity, the total inventory cost will be $690,000. At
50% design capacity, the chip costs will be half that. Since the research phase only involves
prototype development, and not revenue generation, there are no inventory costs.
Finally, the operating costs include research and development, and sales costs. These
costs only apply during the stage beyond the research stage. They have been estimated as a
percentage of revenue.
The Gantt chart in Figure VII.1 on the facing page outlines a potential two day
operational period scenario in order to determine the number of technicians required for optimal
sequencing throughput. In consideration of the number or lab technicians required in order to
manage the throughput of the system, it is important to consider the amount of time required for
the preparation of the key parts solutions required for sequencing. The most important steps are
the genome extraction and amplification, and the preparation of the waveguides for sequencing.
Since the genome isolation requires a 16 hour incubation period for maximum extraction, it is
unnecessary to wait for incubation during the work day. Therefore, it is best to prepare the DNA
solution at the end of the work day, and then allow for incubation overnight. Upon returning to
work the next morning, the amplified genomic DNA is ready for use. It is important to note that a
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large number of samples can all be prepared in one batch, so that this time scale assumes the
preparation of approximately 2 days worth of DNA for sequencing for one day of DNA extraction.
The preparation of a single chip, including immobilization of the DNA polymerase and the
loading of the DNA takes approximately 40 minutes. In order to safely meet throughput
requirements, 13 chips must be prepared in one day. As Figure VII.1 demonstrates, it is possible
for a single technician to prepare all 13 chips in a single day, not accounting for necessary breaks.
Once the chips are prepared, they can be set in the sequencing apparatus and allowed to run
overnight. Assuming a very efficient lab technician that does not eat and works 20 minutes of
overtime, it is possible that in this scenario, one lab technician can handle the throughput required
to meet the sequencing goals. However, in order to account for potential complications and
problems, another lab technician should be available so that the work load can be divided, easily
meeting the throughput required. Also, this scenario assumes that several chips cannot be
prepared at once. Considering the small size and standardization of the chips, it is reasonable to
assume that several, if not all, of the chips used in one day cannot be prepared at the same time, up
to the point of the addition of the DNA, which is actually the final step in the preparation of the
chips. Assuming this, two lab technicians should be sufficient to handle the throughput
requirements.
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The company will use a 5 year MACRs depreciation schedule because the accelerated tax
schedule will provide the company with tax savings. Depreciation is a non-cash expense but it
still affects the pre-tax income, from which taxes are deducted. If the pre-tax income decreases,
taxes will also decrease. And tax, unlike depreciation, is a cash expense. An accelerated
depreciation schedule for short lived projects like this will have a significant impact on the NPV
and MIRR analysis. The depreciation percentages for MACRS in order are 20%, 32%, 19.2%,
11.52%, 11.52%, and 5.76%.

Depreciation Schedule
MACR Tax Schedule:

20.00%

32.00%

19.20%

11.52%

11.52%

Year

2010

2011

2012

2013

2014

Series A Equipment

$
708.3
$ (141.7)

$ (226.7)

$ (136.0)

$
(81.6)

$ (535.4)

$ (856.6)

$
(513.9)

Depreciation

$ 2,676.8

Series B Equipment
Depreciation
$
-

$
708.3

$ 3,243.4

$ 2,481.4

$ 1,488.9

PPE Purchased/(Sold)

708.3

2,676.8

-

-

-

Less: Total Depreciation

$
708.3

(141.7)

(762.0)

(992.6)

(595.5)

$ 3,243.4

$ 2,481.4

$ 1,488.9

$ 893.3

Beginning Net PPE

Ending Net PPE

Table VII.4 Depreciation Schedule using the 5 year MACRs schedule. ($ in thousands).
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The series A equipment is the research equipment purchase, and the series B equipment
is the sales equipment purchase. The ending net PPE figures are balance sheet items and
represent how much property and equipment the company owns. The total depreciation is what
will appear on the income statement and will decrease the pre-tax income. In a later section, we
will explore a what-if scenario of when the research stage takes two years instead of one. In that
case, the series B equipment and its depreciations would simply be shifted to the right one year
and the total depreciations would be changed as well.

VII.3 Income Statement
Income Statement
2010

2011

2012

2013

2014

$ -

$ 15,000.0

$ 30,000.0

$ 30,000.0

$ 30,000.0

Cost of Sales
Gross Profit
Operating, SG&A
Expenses

(172.6)
(172.6)

(643.6)
14,356.4

(988.6)
29,011.4

(988.6)
29,011.4

(988.6)
29,011.4

(292.0)

(2,380.0)

(3,730.0)

(3,730.0)

(3,730.0)

Depreciation
Pre-Tax Income

(464.6)

(141.7)
11,834.7

(762.0)
24,519.4

(992.6)
24,288.8

(595.5)
24,685.9

185.8
$ (278.8)

(4,733.9)
$ 7,100.8

(9,807.8)
$ 14,711.6

(9,715.5)
$ 14,573.3

(9,874.3)
$ 14,811.5

Design Capacity

0%

50%

100%

100%

100%

Margins
Gross Margin
Profit Margin

0.0%
0.0%

95.7%
47.3%

96.7%
49.0%

96.7%
48.6%

96.7%
49.4%

Year
Revenue

# Tax @ 40%
Net Income

Table VII.5 The income Statement showing the gross and profit margins. ($ in thousands).
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The total costs are divided into cost of sales and operating, SG&A expenses. The cost of
sales (also known as costs of goods sold, COGS) includes costs that are directly involved in the
making of the goods. It is a sum of fixed costs and variable costs. The fixed costs include rent
and overhead because rent and overhead costs do not vary with the number of goods sold. The
variable costs are the inventory costs because the inventory cost is a function of how many
genomes are sequenced. Subtracting the cost of sales from the revenue is the gross profit. The
gross margin is a percentage showing how much money is left from the revenue after paying for
the cost of sales. The operating and SG&A (Selling, general, and administrative) expenses are
costs that are associated with managing the business. These costs are mainly salary, but also
include the research and development cost and the sales cost. Subtracting these new expenses
and the depreciation gives the pre-tax income.
Federal taxes are set around 35% but when state tax is added, the tax can be rounded up
to 40%. In the first year, because the company has actually lost money, the tax figure is positive
and the company actually receives money from the government. This is called negative taxes, or
tax shield. Sometimes this does not apply, but we will assume that this holds with our company.
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VII.4 Working Capital
The income statement led us to net income. But net income is not equivalent to cash. In
order to get to cash figures, and subsequent NPV and IRR analysis, we need to adjust net income
for cash items. There are multiple cash items to adjust for. Change in working capital is one of
them.
Working capital is how much capital a company needs to operate normally. If a company
makes $1000, it can’t give all of it to the owner: a portion of it has to be allocated for the
company to run its day-to-day operations. This allocated cash is the working capital and it can be
described as current assets minus current liabilities. Current assets are things the company has
that can be converted to cash quickly. Current liabilities are bills and debts the company has to
pay quickly. Working capital is current assets minus current liabilities because it is the money
left over after having paid all its imminent bills.
There are four main working capital items we will work with: accounts receivables,
inventory, accounts payable, and cash reserve. Accounts receivables are earnings that haven’t
received cash payment yet. For example, after making a sale, the company records its earnings
even when it hasn’t received cash payment yet. The client usually has about 30~60 days to pay.
We will choose 30 days. Because all account receivables convert into revenue:

=

($)

∗

113

1
365

∗ 30

Equation VII.1

Financial Analysis

Inventory is what the company needs to produce the goods it sells. In our case, they are
the SMRT chips and reagents. Our company will buy new inventory every month.
($)

=

∗

1
365

∗ 30

Equation VII.2

Accounts payable is the opposite of accounts receivable: they are bills the company
records (and subtracts from revenue) but haven’t handed in the cash yet. We will pay bills every
30 days. Normally, in the following equation, cost of sales is used instead of rent and operating
cost, but because we have more detailed information, we can modify the equation. Cost of sales
usually has rent, operating costs, and inventory costs all buried inside so many people use cost of
sales as a proxy. Because all account payables turn into rent and operating costs:
+

=

($)

∗

1
365

∗ 30

Equation VII.3

Cash reserve is cash on hand needed to pay for future salary. We will reserve 3 months worth of
salary.

ℎ

=

($)

∗

1
12

ℎ

∗3

ℎ

Change in working capital items change net income into cash.
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Working Capital
2010

2011

2012

2013

2014

Accounts Receivable

$
-

$ 1,232.9

$ 2,465.8

$ 2,465.8

$ 2,465.8

Inventory

-

28.4

56.7

56.7

56.7

Accounts Payable

24.5

135.5

246.5

246.5

246.5

Cash Reserve

73.0

257.5

257.5

257.5

257.5

(Increase)/Decrease in A/R

$
-

$ (1,232.9)

$ (1,232.9)

$ -

$ -

(Increase)/Decrease in Inv

-

(28.4)

(28.4)

-

-

Increase/(Decrease) in A/P

24.5

111.0

111.0

-

-

(Increase)/Decrease in C/R

(73.0)

(184.5)

-

-

-

$ (48.5)

$ (1,334.8)

$ (1,150.3)

$ -

$ -

Year
Working Capital Item Estimates

Changes in Working Capital

Total Change in Working Capital

Table VII.6 Working Capital and Change in Working Capital. ($ in thousands).

Any increase in assets will decrease cash. It makes sense because the company needs to
spend money to buy things. Any decrease in assets will increase cash because selling equipment
or any other asset results in cash. An increase in liability also increases cash. If a company
borrowed money from a bank, it has more money to spend, before having to spend it back. A
decrease in liability results in decrease of cash because the company has to spend cash to pay
back debt.
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An increase in account receivable since last fiscal year should decrease cash because net
income has taken this account but the company hasn’t actually received the money yet. By next
fiscal year, however, the company will have been paid, which is reflected by a decrease in
accounts receivables (assuming no additional A/R accrues). An increase in inventory decreases
cash because the company needs to spend cash to buy inventory. An increase in accounts payable
increases cash because net income is revenue minus accounts payable, but the company hasn’t
paid the bill yet. An increase in cash reserve decreases cash because cash has to be held back to
pay future salary and that cash can’t be used to pay the owners or else the company will cease to
operate normally.
Two other cash items need mentioning. Purchasing PPE (plant, property, and equipment)
decreases cash immediately. However, a PPE purchase isn’t shown on the income statement.
Instead, it is slowly amortized. This is because the income statement reflects the company’s
operational efficiency, which doesn’t necessarily involve one-time cash expenses. Selling of
equipment is the same: it immediately generates cash, but it isn’t part of revenue because
revenue only reflects the company’s natural operations. Selling unwanted equipment isn’t part of
operations: it’s a one-time thing.
Issuing common stock is the same. Issuing common stock to investors (series A and
series B investors) immediately generates cash but isn’t part of revenue. Repurchasing existing
shares from the public market would decrease cash but isn’t reflected on the income statement.
All cash items are found in the cash flow statement.
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VII.5 Free Cash Flow, Terminal Value
After getting change in working capital and other cash items from the cash flow
statement, we can convert net income into free cash flow.

Free Cash Flow
2010

2011

2012

2013

2014

$ (278.8)

$ 7,100.8

$ 14,711.6

$
14,573.3

$
14,811.5

$
-

$
141.7

$ 762.0

$
992.6

$
595.5

(Increase)/Decrease in A/R

-

(1,232.9)

(1,232.9)

-

-

(Increase)/Decrease in Inventory

-

(28.4)

(28.4)

-

-

Increase/(Decrease) in A/P

24.5

111.0

111.0

-

-

(Increase)/Decrease in C/R

(73.0)

(184.5)

-

-

-

Total Change in Working Capital

(48.5)

(1,334.8)

(1,150.3)

-

-

(708.3)

(2,676.8)

-

-

-

1,200.0
$
164.5

3,500.0

-

$ 6,730.9

$ 14,323.4

$
15,565.9

$
15,407.1

Year

Net Income
Cash Flow Statement
Cash From Operating Activities
Plus: Depreciation
Changes in Working Capital

Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock
Free Cash Flow

Table VII.7 Free Cash Flow from Net Income. ($ in thousands).
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The free cash flows are used for NPV and IRR analysis because they represent real cash
received by the owners.
Before conducting NPV and IRR analysis, however, we need to determine the terminal
value of the company. We accomplish this by using the perpetuity growth model:

=

ℎ

∗

(1 + )
−

The cash flow is the last free cash flow. The parameter g is
the growth rate of the cash flow and the company. The
parameter r is the discount rate. This terminal value can be
described as the present value of all the continuing future
cash flows. This concept is highly theoretical because it

Equation VII.5

Terminal Value
$
15,407.1

Last Free Cash
Flow

25%

Discount Rate
Growth Rate
15%
0%

assumes that future cash flows are predictable. Note: when
-15%

Terminal Value
$
154,070.6
$
61,628.2
$
38,517.6

g = 0, the equation simplifies into CF / r, which is the basic
Table VII.8 Terminal Value Examples

perpetuity model.
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VII.6 NPV Valuation
The net present value is a mathematical model used to describe how much richer one
would become today if he were to undertake the investment. It is the sum of all the present
values of every cash flow, which in this case, is the free cash flow and the terminal value. It is a
theoretical model that is heavily dependent on the discount rate.

NPV Calculation @ 25%
Year
T

2009

2010

2011

2012

2013

2014

Terminal Value

0

1

2

3

4

5

6

$ 164.5

$ 6,730.9

$ 14,323.4

$ 15,565.9

$ 15,407.1

$ 61,628.2

Free Cash
Flow
Discount Rate

50%

Present Value

$ 109.7
$ (1,200.0)

$ (3,500.0)

Discount Rate

0%

25%

Present Value

$ (1,200.0)

$ (2,800.0)

Investments

25%
$ 4,307.8

25%

25%

25%

25%

$ 7,333.6

$ 6,375.8

$ 5,048.6

$ 16,155.5

Sum of All Present Values (NPV)

$ 35,330.9

Table VII.9 Net Present Value Calculation Using Discount Rate of 25%. ($ in thousands).

The discount rate used depends on the industry. The riskier the industry, the higher the
discount rate is. Because the biotechnology industry is risky and unpredictable, the discount rate
used will be 25% and 30%. Both will be used to create a range of multiple NPVs. The discount
rate during the research stage, however, will be 50% because developing new technology is
much riskier. Table 8 summarizes the calculations using a discount rate of 25%.
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In order to calculate the net present values, all the projected free cash flows and terminal
value are discounted back into present values. Those present values are then summed. Next, we
have to subtract out the present values of the cost of the project – the initial investments. Our
calculation becomes trickier because we have two rounds of investments at two different times
from two different investors. Some qualitative reasoning is required. The present value of the
first investment, the series A investment of $1.2MM, is equal to itself because it is not a future
cash flow: it is a cash outflow that occurs in the present. The second investment, the series B
investment of $3.5MM, occurs at the end of 2010, when a working prototype has been
developed. Unlike the first cash inflow that is discounted at a rate of 50%, the series B
investment is actually discounted at a rate of 25%. This is because the purpose of the 50%
discount rate was to take into account the extraordinary risk of developing new technology.
Because series B is funded only when that extra risk is taken away, it is discounted at 25%, not
50%.
Also note that the terminal value of the company is also discounted to the present. This is
because the terminal value is a future projected value. We have assumed that the growth rate will
be 0%. The sum of all the present values is the net present value: it is called net present value
because it adds all the positive future cash flows, and the present negative investments to get a
net sum. This number tells us that undertaking the PennBio project will make the investors
$35MM richer today. Of course, keep in mind that this is only a model and it depends heavily on
several assumptions. It is good practice to do multiple analyses under different scenarios and
assumptions.
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VII.7 Equity Shares
There is another profitability measure called the IRR, but because there are two different
investors, each investing at two different times, we need to create an internal bookkeeping of
how much equity each group of investors own. To clarify, how much of the free cash flows do
the series A investors get to keep, and how much do the series B investors keep?
To get an initial picture, we

Percentage of Investments

compare how much the two investors

FV
Investment Investment

have put into the project. The series
A investors put in $1.2MM at the
beginning and the series B investors
put in $3.5MM one year later.

Series A
Investors
Series B Investors

$
1,800.0

$ 1,200.0
3,500.0

34%
66%

3,500.0
$
5,300.0

Total

Percentage

100%

Because of the time difference, the
Table VII.10 Comparing Percentages of Investments. ($ in thousands).

series A investment needs to be
discounted forward by 50% to compare the two numbers correctly.
From this result, it can be argued that the series B investors should keep 66% of the
company once they come in. On the other hand, because the series A investors have put in more
sweat equity and feel that they undertook more risk that the discount rate doesn’t quite cover,
both could agree that the series A investors will receive more equity. However, for the sake of
simplicity and because the issue of sweat equity is a very subjective one, we will avoid that here.
The series B investors will receive 66% of equity, the series A investors will keep 90% of the
remaining 34%, and the scientists will keep 10% of the remaining 34%. In the case where the
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research stage takes two years, the series A investment will be discounted forward twice by 50%:
series B investors would receive 54%. Table VII.11 summarizes company ownership.

Equity Percentage
Year

2010

2011

2012

2013

2014

2015

Scientists
Series A
Investors
Series B
Investors

10%

3%

3%

3%

3%

3%

90%

31%

31%

31%

31%

31%

0%

66%

66%

66%

66%

66%

100%

100%

100%

100%

100%

100%

$ (1,090.3)

$ 417.5

$ 7,751.0

$ 14,126.8

$ 19,175.4

$ 35,330.9

Total
NPV @ 25%
Investments

(1,200.0)

(2,800.0)

Shares Values vs. Time
Scientists
Series A
Investors
Series B
Investors

$ -

$
14.2

$ 263.2

$ 479.8

$ 651.2

$ 1,199.9

-

127.6

2,369.2

4,318.0

5,861.2

10,799.2

-

275.7

5,118.6

9,329.0

12,663.0

23,331.7

Total

$ -

$ 417.5

$ 7,751.0

$ 14,126.8

$ 19,175.4

$ 35,330.9

Table VII.11 Equity Percentage and Share Values of Owners. ($ in thousands).

By calculating the NPV values at each year, we can also calculate each owner’s share value as a
function of time.
Defining equity percentage is an important bookkeeping task because percentage of
ownership determines how much of the free cash flows generated each group will get to keep.
Using that information, we can conduct a rate of return analysis.
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VII.8 MIRR Analysis
Conventional rate of return analysis uses the IRR (internal rate of return) figure.
However, there are many flaws in that model. Consequently, using IRR for our analysis would
yield highly overstated and inaccurate results, especially in projects with large positive cash
flows. In using the IRR, the calculation assumes that the free cash flows will be reinvested at the
rate being calculated. This is a critical mistake because in the PennBio investment, there are only
two rounds of investments and none of the free cash flows are being reinvested. In fact,
McKinsey consultants advise avoiding using the IRR.
The alternative rate of return metric will be the MIRR (Modified internal rate of return).
In this metric, we must specify the finance rate and the reinvest rate. The finance rate is the APR
(Annual percentage rate) the company would have to pay to debt lenders if there are any negative
cash flows. The reinvest rate is the rate the owners would receive on the positive cash flows. For
the finance rate, we will assume a standard 4.4% on a bank term loan. For the reinvest rate, we
will assume a 4.9% return. It is the current yield on a 3 month and 6 month US Treasury bill,
which can be seen as the risk free rate. Alternatively, we could use a higher reinvest rate since
the investors can be assumed to experienced enough to earn more than the risk free rate,
especially if they are investing in the risky biotech industry. However, we chose the risk free rate
to be conservative in our profitability analysis.
The MIRR calculations are simple: First, the investment is defined. Then all the free cash
flows the investor would receive are divided by the equity percentage. An MIRR can be
determined from those figures. The following table summarizes the calculations.
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MIRR Calculations
2010

2011

2012

2013

2014

2015

$ 164.5

$ 6,730.9

$ 14,323.4

$ 15,565.9

$ 15,407.1

$ 61,628.2

Equity
Percentage
Series A

90%

31%

31%

31%

31%

31%

Series B

0%

66%

66%

66%

66%

66%

Cash Flows
Series A

Investmen
t
$ (1,200.0)

Divided Free Cash Flows
$ 148.0
$ 2,665.4
$ 5,672.1

$ 6,164.1

$ 6,101.2

Series B

$ (3,500.0)

$ 3,769.3

$ 8,628.0

$ 34,511.8

Year
Free Cash Flows

Series A MIRR

77%

Series B MIRR

87%

$ 8,021.1

$ 8,716.9

$ 24,404.8

Table VII.12 MIRR Calculation. Finance rate at Term loan APR of 4.4%, reinvest rate at 6-month T-bill of 4.9%. ($ in
thousands).

Note that an IRR calculation would yield around 150% returns, a grossly overstated
figure. Also, the series B cash flow has one less term. This is because the series B investors came
in one year after the series A investors did.
To summarize the first part of our financial analysis, we created a pro forma income
statement, adjusted to get free cash flows, and then used those to arrive at an NPV and MIRR
analysis. The following page summarizes everything we have done so far. There are two terminal
values: the one on the top uses a discount rate of 30% and the one on the bottom uses 25%.
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NPV @ 30%
NPV @ 25%

Series A @ 31% of Equity
Series B @ 66% of Equity

Income Statement
Revenue
Cost of Sales
Operating, SG&A Expenses
Depreciation
Pre-Tax Income
# Tax @ 40%
Net Income
The two investments
Cash Flow Statement
Cash From Operating Activities
Plus: Depreciation
Changes in Working Capital
(Increase)/Decrease in A/R
(Increase)/Decrease in Inventory
Increase/(Decrease) in A/P
(Increase)/Decrease in C/R
Total Change in Working Capital
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock
Free Cash Flow
Discount Rate @ 30%
% of Design Capacity
Discount Rate @ 25%

Year

2012

$ 141.7
$ (1,232.9)
(28.4)
111.0
(184.5)
$ (1,334.8)
(2,676.8)

$ $ 24.5
(73.0)
$ (48.5)
(708.3)

-

$ (1,232.9)
(28.4)
111.0
$ (1,150.3)

$ 762.0

2
3
$ 15,000.0
$ 30,000.0
(643.6)
(988.6)
(2,380.0)
(3,730.0)
(141.7)
(762.0)
11,834.7
24,519.4
(4,733.9)
(9,807.8)
$ 7,100.8
$ 14,711.6
$ (2,692.3) $ (2,800.00)

2011

30% $

$ 4,378.1
10,279.3

$ 15,565.9
30%
100%
25%

-

$ $ -

$ 992.6

4
$ 30,000.0
(988.6)
(3,730.0)
(992.6)
24,288.8
(9,715.5)
$ 14,573.3

2013

$ 4,757.9
10,174.5

$ 15,407.1
30%
100%
25%

-

$ $ -

$ 595.5

5
$ 30,000.0
(988.6)
(3,730.0)
(595.5)
24,685.9
(9,874.3)
$ 14,811.5
Terminal Growth

2014

$ 4,709.3
40,697.9

$ 18,837.3

$ 51,356.9 (Terminal
$ 61,628.2 Value)
30%
100%
25%

0%

6

2015

$ 26,959
Series A MIRR
77%
$ 35,331
Series B MIRR
87%
109.65 $ 3,982.80 $
6,519.51 $ 5,450.04 $ 4,149.57 $ 10,639.92

1,200.0
3,500.0
$ 164.5
$ 6,730.9
$ 14,323.4
50%
30%
30%
0%
50%
100%
50%
25%
25%
Investment Divided Free Cash Flows
$ (1,200.0)
$ 148.0
$ 2,057.4
(3,500.0)
4,445.0
9,458.8

$

1
$ (172.6)
(292.0)
(464.6)
185.8
$ (278.8)
(1,200.00)

2010
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VII.9 What-If Scenarios
So far, the previous financial analysis holds under certain assumptions. But what if those
assumptions aren’t true? What if the project undergoes certain deviations? Then what will
happen to our financial analysis?
To observe, how the project’s profitability would change, different case scenarios were
defined for the research stage, scale up and sales stage, and the terminal stage. The following
table summarizes the different case scenarios and their results.

What-If Scenarios
Research Stage
Best Case

S1)

The start up stage takes one year, as planned.

Worst Case

S2)

The start up stage unexpectedly takes two years.

Scale Up and Sales Stage
Best Case
D1) The first year of sales has 50% of design capacity, as planned. The remaining
three years run at full 100% capacity.
Worst Case

Terminal Stage
Best Case

D2) The first year of sales has 30% capacity. The next year's capacity is 70%.
The remaining two years of sales have full 100% capacity.

T1)

The company stays profitable. The revenue stays constant perpetually.

Middle Case
T2)
15%

The company starts to decline due to rising competitors.
Earnings decrease 15% each year.

Worst Case
T3)
50%

Due to an improved rival technology, customers stop showing up immediately.
Equipments are sold at 50% of face value, a total of $1.69MM.

Table VII.13 What If Scenarios
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Scenario Summary
Tree
S1

D1

D2

S2

D1

D2

Case
1
2
3
4
5
6
7
8
9
10
11
12

T1
T2
T3
T1
T2
T3
T1
T2
T3
T1
T2
T3

NPV @ 30%
$
26,959
22,349
16,670
23,025
18,414
12,736
26,733
22,122
16,444
22,799
18,188
12,510

NPV @ 25%
$
35,331
27,758
19,619
30,964
23,392
15,253
35,103
27,530
19,391
30,737
23,164
15,025

Series A
MIRR
77%
69%
58%
75%
66%
53%
58%
58%
58%
54%
54%
54%

Series B
MIRR
87%
76%
62%
84%
73%
57%
81%
71%
57%
78%
67%
52%

NPV and MIRR Range
High

Medium

Low

(Average of top 3)

(Median)

(Average of bottom 3)

$ 33,799.4

$ 22,573.7

$ 13,423.3

Series A

73%

58%

54%

Series B

84%

72%

55%

NPV

Table VII.14 Complete NPV and MIRR Summary of 12 What-If Scenarios. ($ in thousands).

Even under these various scenarios, the PennBio project looks very comfortable. A copy
of all 12 pro forma is provided in Appendix F. One crucial assumption to note here is that all
these scenarios have the genome price selling at $10,000. As mentioned in the introduction, the
revenue generation is the most important assumption because all our financial analysis depends
on it.
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VII.10 Price Sensitivity Analysis
We will repeat the same analysis under various genome prices to see under which prices
the project would lose money. The following table summarizes the results. The genome prices
range from $10,000 to $500.

Genome Price Sensitivity Analysis
NPV
Genome Price

High
$
33,799.4

MIRR

Medium
$
22,573.7

Low
$
13,423.3

High A

Medium

Low

High B

Medium

Low

73%

58%

54%

84%

72%

55%

$ 33,799

$ 22,574

$ 13,423

73%

58%

54%

84%

72%

55%

9,000

29,806

19,780

11,628

71%

56%

51%

80%

69%

52%

8,000

25,797

16,969

9,815

67%

53%

48%

76%

64%

49%

7,000

21,788

14,157

8,002

63%

49%

45%

71%

60%

45%

6,000

17,794

11,364

6,206

59%

45%

41%

65%

55%

40%

5,000

13,785

8,553

4,393

54%

40%

36%

59%

49%

35%

4,000

9,776

5,737

2,580

48%

35%

31%

51%

41%

29%

3,000

5,783

2,874

784

40%

27%

23%

41%

32%

21%

2,000

1,773

83

(1,029)

28%

17%

13%

27%

18%

10%

1,000

(2,211)

(2,609)

(2,971)

5%

-2%

-8%

-2%

-7%

-10%

(3,530.7)

(4,045.7)

(4,402.1)

-16%

-30%

-31%

-22%

-88%

-100%

$ 10,000

500

Breakeven
Price

$ 1,600.0

,553.5

$ 2,000.0

$ 2,600.0

1,951.7

2,582.5

Table VII.15 Genome Price Sensitivity Analysis for NPV and MIRR. ($ in thousands).
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As mentioned before, the price of the genome is difficult to nail down. But we see here
that charging at least $3000 per genome can still make returns. This is a very comfortable price
margin, especially considering that one of the existing competitors, Knome®, is charging
$100,000.

VII.11 Growth Case
We look at one final scenario. When the company’s margins are healthy, it would be wise to
expand its operations. This would only happen when the research stage, scale up stage, and the
development stage occur as planned – that is, a case 1 scenario. This would be the best case scenario. In
our financial model, we will make the design capacity grow exponentially at 50% during the sales stage:
the company will operate at a capacity of 100%, 150%, and 225%. Here, the average of the 25% and 30%
NPV is $54MM, the series A MIRR is 95%, and the series B MIRR is 110%. At the end of Appendix F,
is the pro forma for this case.

VII.12 Conclusions
The entire financial analysis has provided ample evidence to show that PennBio would be
a profitable investment. Next, the what-if scenarios have shown that the investors would receive
high returns, even under worst case scenarios. Finally, the sensitivity analysis has revealed that
an ample price margin exists before the investors lose their capital.
Of course, financial models are insightful, but they are still models. They help to guide
the investors and to reduce as much risk as possible. Models do not determine the future. And
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because no one can predict the future, there will always be a degree of financial risk. But our
financial analysis has covered as much as possible. One reason why the venture looks so
profitable is chiefly due to the nature of the market: It is a biotech firm in an early, immature
market. Not many competitors exist with our technology. And this is typically what one would
expect in such settings. Until the market matures, profit margins will be remarkably high.
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Conclusions

The primary objective of this venture was to characterize and develop a novel wholegenome sequencing technique with a particular focus on accuracy and extraordinary throughput.
This was achieved through the application of cutting-edge single-molecule, real-time detection
technology. Fundamental to this approach are several breakthroughs which pushed production to
new heights while maintaining sequence fidelity. Zero-mode waveguides, which simultaneously
provide exceptionally high signal-to-noise ratios and the geometric consistency that permits oneto-one waveguide to pixel mapping, allow for unprecedented clarity in single-molecule
observation. Novel phospho-linked nucleotides, which emit signal pulses while being
incorporated into sequenced DNA then go dark as their fluorescent moiety is cleaved from the
unadultered growing complementary strand, facilitate unparalleled sequence-reads and
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polymerization rates. Two precision-aligned EMCCD cameras collect this high-quality signal
and relay it to a powerful server bank, where it is converted into a complete, personal genome
sequence using a unique two-color ratio approach, and custom-optimized sequence alignment
algorithms.
At full capacity, PennBio can supply 1 genome per SMRT chip station per day. With a
mere 13 stations, production is expected to reach 3,000 full genomes per year. This level of
throughput well exceeds the industry status quo, and in conjunction with the minimum of capital
investment per unit output, translates into affordable and readily available genomic data for our
customers. And at a retail price of $4,000 per genome, we stand to gross up to $12.0 million per
year in revenues. We offer our investors a unique opportunity to profit financially from the
relentless advances made every day in understanding and practical use of the human genome.
Moreover, this financial situation appears to be optimal in the current technological
environment. Using 1-to-1 polymerase to pixel ratios, and relatively simple optics, we have
minimized our fixed costs, while the utilization of high-performance enzymes and streamlined
data analysis maximizes revenue. We therefore do not believe that another whole-genome
sequencing firm could enter the market and be more profitable than PennBio – not without
substantial advances in optical detection, computing, and biotechnology.
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Appendix A:
Reagent Specifications
A.1

Sequencing-by-Synthesis Reagents

A.2

Deoxyribonucleotide Fluropentaphosphate Reagents

A.3

Deoxyribonucleotide Fluropentaphosphates

A.4

Proteins
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Sequencing-by-Synthesis Reagents
Species

Formula

Manufacturer

Price ($)

Biotin

C10H16N2O3S

(Various)

--

Biotinpolyethyleneglycoltrimethylsilane

--

Laysan Bio

480
per 500 mg

Polyvinylphosphonic
acid

(C2H5PO3)n

Sigma-Aldrich

215
per gram

See individual Nucleotides
on page B.2

5’-NNNNNN3’

Fidelity Systems

22
per 4 µg

(Various)

50mM ACES:
C4H10N2O4S
75mM KC2O2
5mM
dithiothreitol:
C4H10O2S2

(Various)

--

NaOH

The Science
Company

11.5
per 500 g

Random Hexamers

Reaction Buffer

Structure

Sodium Hydroxide
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Deoxyribonucleotide Fluoropentaphosphate Reagents
Species

Structure

Formula

Manufacturer

Price ($)

Guanine

C5H5N5O

Cole-Parmer

25.30
per 25 g

Adenine

C5H5N5

Cole-Parmer

96.30
per 25 g

Thymine

C5H6N2O2

Cole-Parmer

47.10
per 25 g

Cytosine

C4H5N3O

Cole-Parmer

56.60
per 5 g
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Species

Structure

Formula

Manufacturer

Price ($)

Fmoc-6aminohexylphosphate

C21H25NO3

AnaSpec

120
per gram

Anhydrous acetonitrile

C2H3N

Sigma-Aldrich

761
per 18 liters

Anhydrous
triethylphosphate

C6H15O4P

Sigma-Aldrich

156.50
per 4 liters

Phospohrus oxychloride

POCl3

Sigma-Aldrich

105
per 100 mL

Triethylamine

C6H15N

Sigma-Aldrich

102
per 2 liters

Bicarbonate

HCO3

Sigma-Aldrich

47.30
per 500 grams
(NH4+ salt)

-
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Species

Structure

Formula

Manufacturer

Price ($)

Methanol

CH3OH

Sigma-Aldrich

40.90
per liter

Diethyl Ether

C4H10O

Sigma-Aldrich

199.50
per 4 liters

Dimethylformamide

C3H7NO

Sigma-Aldrich

24
per 250 mL

1,1’-Carbonyldiimidazole

C7H6N4O

Sigma-Aldrich

36.70
per 10 g

tributylamine

[CH3(CH2)3]3N

Cole-Parmer

35.90

Phosphoric Acid

H3PO4

Cole-Parmer

47.74
per 500mL
(85% sol’n)
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Species

Structure

Formula

Manufacturer

Price ($)

Magnesium Chloride

Cl – Mg – Cl

MgCl2

Gallade Chemical

104.96
per 5 g

Alexa Fluor A555

Invitrogen

240
per 1 mg

Alexa Fluor A568

Invitrogen

240
per 1 mg

Alexa Fluor A647

Invitrogen

240
per 1 mg

Invitrogen

240
per 1 mg

Alexa Fluor A660

Not Available
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Deoxyribonucleotide Fluoropentaphosphates

Molecular structures of the phospho-linked deoxyribonucleotide pentaphosphates, and their normalized
fluorescence emission spectra of their fluorophores. The two excitation wavelengths used are indicated
by arrows (532 and 643nm). Reproduced from Eid, et al. 2009.
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Proteins:
φ29 Polymerase

Reproduced from Berman, et al. 2007.
Theoretical molecular weight: 66,714 Daltons.
Quaternary Structure: Monomeric.
Manufacturer: New England Biolabs
Source: An E. coli strain that carries the phi29 DNA Polymerase gene from bacteriophage phi29
Cost: 1,250 units at 10,000 units/ml for $244.00
One unit is defined as the amount of enzyme that will incorporate 0.5 pmol of dNTP into acid
insoluble material in 10 minutes at 30°C.
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Streptavidin

Reproduced from Berman HM, et al. 2000.
Theoretical molecular weight: 52,800 Daltons.
Quaternary structure: Tetrameric.
Manufacturer: New England Biolabs
Source: Streptomyces avidinii
Cost: 1 mg as 1 mg/ml for $56.00
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DNA Extraction and Isolation
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Appendix B: DNA Extraction and Isolation

Protocol provided by QIAGEN:
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Reproduced from J. Korlach et al. 2008
The synthesis is described using Alexa Fluor 488-aminohexyl-dG5P (A488-dG5P) as an
example.
Fmoc-6-aminohexylphosphate: Fmoc-6-aminohexanol (1 g, 2.94 mMoles) was coevaporated with anhydrous acetonitrile (2 20ml) then suspended in 10 ml anhydrous
triethylphosphate. Phosphorus oxychloride (550 μl, 5.88 mMoles, 2 eq.) was added to the
stirring suspension. After 2 hours, HPLC showed disappearance of the Fmoc-aminohexanol.
The reaction was quenched by the addition of 100 ml 0.1M triethylamine bicarbonate (pH
6.8) and stirred for 30 minutes. The compound was purified by reverse phase HPLC on a
Waters Xterra C18 RP 30 100 column using an acetonitrile gradient in 0.1M triethylamine
bicarbonate. The fractions containing product were evaporated, followed by coevaporation with methanol (2 ). The residue was triturated twice with 100 ml diethylether
and dried under vacuum to give a white powder. Yield: 1.24 g, 68% as bis-triethylamine
salt. HPLC 98%.
Fmoc-6-aminohexyldiphosphate: Fmoc-6-aminohexylphosphate (200 mg, 320 μMoles) was
co-evaporated twice with anhydrous acetonitrile, then taken up in 2 ml anhydrous DMF.
1,1'-Carbonyldiimidazole (CDI, 207 mg, 1280 μMoles, 4 Eq.) was added and stirred at
ambient temperature for 4 hours. Methanol (77 μl, 1920 μMoles) was added and stirred 30
minutes. Tributylamine-H2PO4 (3200 μMoles, 10 Eq.), prepared by mixing equimolar
amounts of tributylamine and 85% phosphoric acid followed by co-evaporation 3 times
with anhydrous acetonitrile, was dissolved in 4 ml anhydrous DMF and added to the
reaction. The reaction mixture was stirred 16 hours. HPLC showed 3% Fmocaminohexylphosphate remaining. The reaction mixture was diluted to 50 ml with 0.1M
TEAB, and was purified by RP HPLC on a Waters Xterra C18 RP 30 100 column using an
acetonitrile gradient in 0.1M triethylamine bicarbonate. The fractions containing product
were evaporated, followed by co-evaporation with methanol (2 ). The residue was coevaporated with anhydrous acetonitrile. Yield: 186 mg, 73% as tris-TEA salt. HPLC 96%.
Aminohexyl-dG5P: Fmoc-6-aminohexyldiphosphate (186 mg, 233 μMoles) was coevaporated twice with anhydrous acetonitrile, then taken up in 3ml anhydrous DMF. CDI
(150 mg, 930 μMoles, 4 Eq.) was added and stirred at ambient temperature for 4 hours.
Methanol (56 μl, 1400 μMoles) was added and stirred 30 minutes. dGTP (TEA salt, 350
μMoles, 1.5 Eq.) was co-evaporated 3 times with anhydrous acetonitrile and suspended in 2
ml anhydrous DMF. The Fmoc-aminohexyldiphosphoimidazolate reaction was added to the
dGTP solution followed by anhydrous MgCl2 (3500 μMoles, 333 mg, 10 Eq.). The reaction
was stirred 18 hours. HPLC showed 28% of the Fmoc-aminohexyldiphosphate converted to
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Fmoc-aminohexyl-dG5P. The reaction mixture was diluted to 125 ml with 0.1M TEAB, and
was purified by RP HPLC on a Waters Xterra C18 RP 30 100 column using an acetonitrile
gradient in 0.1M triethylamine bicarbonate. The fractions containing product were
evaporated, followed by co-evaporation with methanol (2 ). The residue was taken up in
20 ml 10% TEA/water and stirred 16 hours to remove the Fmoc protecting group from the
amine on the linker. Triethylamine was evaporated, water was added to 25 ml and the
solution was extracted 3 times with 25 ml diethyl ether. The product was purified from the
aqueous layer by anion exchange chromatography on Q sepharose FF using a TEAB
gradient. Yield 42 μMoles, 18%, HPLC 98%.
Alexa Fluor 488-aminohexyl-dG5P (A488-dG5P): Aminohexyl-dG5P (1 μMole) was dissolved
in 0.05 M NaHCO3 pH 8.7 (200 μl) and was added to 1 mg Alexa Fluor 488-TFP ester
(Invitrogen, Carlsbad, CA, USA). The mixture was briefly sonicated. After 4 hours, HPLC
showed no active ester remaining. The product was identified by characteristic PDA scan.
The compound was purified by IEX on Q sepharose FF with a TEAB gradient. The product
was further purified by RP HPLC on a Waters Xterra RP C18 19 100 column using an
acetonitrile gradient in 0.1M TEAB. The fractions containing pure product were
evaporated, followed by co-evaporation with methanol (2 ). The residue was dissolved in
water and was quantitated by UV-Vis spectrophotometry. Yield 370 nMoles 37%, HPLC
99%.
The other dNTPs were derivatized with Alexa Fluor 633 NHS ester (aminohexyl-dA5P),
Alexa Fluor 680 NHS ester (aminohexyl-dC5P), and Alexa Fluor 568 NHS ester
(aminohexyl-dT5P).
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Synthesis Scheme:

152

Appendix D:
Equipment Specifications
D.1

Microscopes and Peripherals

D.2

EMCCD Cameras

D.3

Nanopositioning stages

D.4

Signal Processing Servers

D.5

Reassembly Servers
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Olympus IX71 Inverted Research Microscope

Objective Lens

UPLSAPO 60XW
◊
◊
◊
◊

Illumination Source

Plan apochromat
Water immersion
NA = 1.20
WD = 0.28 mm
U-LH100HGAPO Mercury Lamp

◊
◊
◊

Aspherical optics
Apochromatic lens
Average lamp life: 300 hours

Mirror/Filter Unit

U-MWIB2

Unit Price

$30,000
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Andor iXon EM+ DU-897 Back-Illuminated EMCCD

Active Pixels

512 x 512

Pixel Size

16 µm

Image area

8.2 x 8.2 mm

Pixel Well Depth

160,000 (max 220,000)

Gain Register PWD

800,000

Readout Rate

10 MHz (max)

Frame Rate

31 fps

QE at 600 nm

95%

Unit Price

$32,500
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PI P-587 6-Axis Piezo Stage with E-710.6CD Digital Controller

Active Axes

X, Y, Z, θX, θY, θZ

Max Travel (X, Y, Z)

800, 800, 200 µm

Max Angle ( θX, θY, θZ)

±0.5, ±0.5, ±0.5 mrad

Open/Closed Loop
Resolution (X, Y)

0.9/2.2 nm

Open/Closed Loop
Resolution (Z)

0.4/0.7 nm

Open/Closed Loop
Resolution (θX, θY)

0.05/0.1 mrad

Open/Closed Loop
Resolution (θZ)

0.1/0.3 mrad

Automation

Auto-Alignment with CCD Feedback

Unit Price

$72,000
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IBM System x3450 79483CX (Signal Processing Server)

Processor (CPU)

Quad-Core Intel Xeon E5462

Processor Speed

2.80 GHz

CPUs

2

Front Side Bus

1 GHz

Internal L2 Cache

12 MB

RAM

8 GB (800 MHz DDR2)

Hard Disk

250 GB, 7200 RPM SATA II

Communications

Integrated Dual Gigabit Ethernet

Form Factor

1U Rack

Unit Price

$4,000
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IBM System p560 Express 8234-EMA2 (Reassembly Server)

Processor (CPU)

8-Core IBM POWER6

Processor Speed

3.6 GHz

CPUs

1

Front Side Bus

1 GHz

Int. L2/L3 Cache

8 MB / 32 MB

RAM

8 GB (800 MHz DDR2)

Hard Disk

2 x 146 GB, 15,000 RPM SAS

Communications

Integrated Dual Gigabit Ethernet

Form Factor

4U Rack

Unit Price

$70,650
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Appendix E:
MATLAB Simulation Code
E.1

Program Framework

E.2

Local Alignment

E.3

Vote Counting

E.4

Base Assignment

E.5

Representative Sensitivity Analysis

E.6

Dual-Camera Peak Identification
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Program Framework with Genome Generation Routine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

function [finalerrorrate snpgenome finalgenome] = genome(genlength,delrate,errorrate,mult)
clear snpgenome finalgenome votefrac maxm index errorloc errorpos error half snppos ...
fragcell alignment score start counter finalerrorrate
% -- Set sequence constants -- %
fragmean = 1000;
fragstdev = 250;
snprate = 1/1000;
% -- Set alignment parameters -- %
gapo = 4;
gape = 21;
% -- Set counter variables -- %
fragind = 1;
dels = 0;
errs = 0;
snps = 0;
% -- Estimate size of fragment library cell array -- %
fragcell = cell(1,round(length(tmv)*mult/(1.2*fragmean)));
% -- Preallocate vote counting matrices -- %
Avotecount = zeros(1,genlength);
Cvotecount = zeros(1,genlength);
Tvotecount = zeros(1,genlength);
Gvotecount = zeros(1,genlength);
Xvotecount = zeros(1,genlength);
sumcount = zeros(1,genlength);
votefrac = zeros(5,genlength);
% -- Preallocate error analysis cell arrays -- %
half = cell(0,0);
error = cell(0,0);
errorpos = cell(1,genlength);
errorloc = cell(0,0);
% -- Generate reference (consensus) genome -- %
tmv = randseq(genlength);
tmv = nt2int(tmv);

%%%%%%%%%
%SNP Insertion%
%%%%%%%%%
snplambda = genlength*snprate;
m = -round((5*snplambda));
snppos = cell(0,genlength);
snpgenome = tmv;
while m <= genlength
clear vvv
vvv = round(exprnd(1/snprate));
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56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117

if (vvv + m) <= 0
m = m + vvv;
elseif ((vvv + m) > 0)
if (vvv+m) < genlength
uuu = unidrnd(4);
snpgenome(m+vvv) = uuu;
snppos{1,m+vvv} = 1;
m = m + vvv;
snps = snps + 1;
else
m = m + vvv;
end
end
end
genlength = length(snpgenome);

%%%%%%%%%
%Fragmentation%
%%%%%%%%%
length1 = 0;
while length1 <= (mult*genlength)
lastcut = 1;
while (lastcut < genlength)
ttt = unidrnd(50);
fraglength = round(normrnd(fragmean,fragstdev));
cutsite = fraglength + lastcut;
if ttt == 1
if (cutsite >= genlength)
fragcell{1,fragind} = snpgenome(1,lastcut:genlength);
fragind = fragind+1;
else
fragcell{1,fragind} = snpgenome(1,lastcut:cutsite);
fragind = fragind+1;
end
else
lastcut = cutsite;
end
end
length2 = zeros(1,mult*1.5*genlength/fragmean);
for k = 1:length(fragcell)
length2(1,k) = length(fragcell{1,k});
end
length1 = sum(length2(1,:));
end
fragkeep = length(fragcell);

%%%%%%%%%
%Error Insertion%
%%%%%%%%%
for n = 1:fragind-1
errorlambda = length(fragcell{1,n})*errorrate;
m = -round((5*errorlambda));
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118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179

errorfrag = fragcell{1,n};
while m <= length(fragcell{1,n})
clear vvv
vvv = round(exprnd(1/errorrate));
if (vvv + m) <= 0
m = m + vvv;
elseif ((vvv + m) > 0)
if (vvv+m) < length(fragcell{1,n})
uuu = unidrnd(4);
errorfrag(1,(m+vvv)) = uuu;
m = m + vvv;
errs = errs + 1;
else
m = m + vvv;
end
end
end
fragcell{1,n} = errorfrag(1,:);
end

%%%%%%%%%%%
%Deletion Insertion%
%%%%%%%%%%%
for n = 1:fragind-1
k = 1;
uuu = poissrnd(delrate*length(fragcell{1,n}));
delnum = zeros(1,uuu);
fragchar1 = fragcell{1,n};
while k <= uuu+1
gam = round(gamrnd(k,1/delrate));
if gam <= length(fragchar1)
delnum(1,k) = gam;
k = k+1;
else
k = k+1;
end
end
delnum = sort(delnum(1,:));
delfrag = [];
i = 1;
k = 1;
m = 1;
while i <= length(fragchar1)
if k < length(delnum)
if delnum(1,k) == i
k = k + 1;
i = i + 1;
dels = dels + 1;
else
delfrag(1,m) = fragchar1(1,i);
m = m + 1;
i = i + 1;
end
else
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180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238

delfrag(1,m) = fragchar1(1,i);
m = m + 1;
i = i + 1;
end
end
fragcell{1,n} = delfrag;
end

%%%%%%%%%%
%Local Alignment%
%%%%%%%%%%
[Avotecount,Cvotecount,Gvotecount,Tvotecount,Xvotecount,sumcount] = ...
localalign1(Avotecount,Cvotecount,Gvotecount,Tvotecount,Xvotecount,sumcount,...
fragkeep,fragcell,tmv,gapo,gape,genlength);

%%%%%%%%%%%
%Base Assignment%
%%%%%%%%%%%
[finalgenome snpgenome] = baseassign1(snpgenome,genlength,Avotecount,...
Cvotecount,Gvotecount,Tvotecount,Xvotecount,sumcount,votefrac);

%%%%%%%%%%
%Error Evaluation%
%%%%%%%%%%
% -- Count sites with less than 3-fold coverage -- %
for n = 1:genlength
if sumcount(1,n) == 2
half{1,n} = n;
else
end
end
% -- Compare final genome to true sequence -- %
% Determine number and position of errors
for n = 1:genlength
errorpos{1,n} = snpgenome(n) - finalgenome(n);
end
k = 1;
for n = 1:genlength
if errorpos{1,n} ~= 0
error{1,k} = 1;
k = k+1;
end
end
% -- Calculate actual coverage multiplicity -- %
multact = length1/genlength;
% -- Calculate error rate in ppm -- %
finalerrorrate = 1000000*(length(error)/genlength);
end
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Local Alignment Subroutine
1
2
3
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

function [Avotecount,Cvotecount,Gvotecount,Tvotecount,Xvotecount,sumcount] = ...
localalign (Avotecount,Cvotecount,Gvotecount,Tvotecount,Xvotecount,sumcount, ...
fragkeep,fragcell,tmv,gapo,gape,genlength)
for n = 1:fragkeep-1
if length(fragcell{1,n}) > 1
% -- A single fragment is selected from the fragment library -- %
frag = fragcell{1,n};
length3 = length(frag);
% -- A shorter fragment is created from the first 10 bases -- %
if length3 > 10
short = frag(1:10);
else
short = frag;
end
% -- This short fragment is aligned with the reference genome, recording starting point-- %
[scorevalue1 alignvalue1 startvalue] = swalign(short, tmv,...
'alphabet','nt','gapopen',gapo,'extendgap',gape);
startvalue = startvalue(2,1);
if startvalue<=1
incr1 = 0;
startvalue = 1;
else
incr1 = 1;
end
if genlength-startvalue<=(20+length3)
incr2 = genlength-startvalue-length3;
elseif genlength-startvalue>(20+length3)
incr2 = 20;
end
% -- The full fragment is aligned to the stretch of reference genome immediately after the starting point -- %
[scorevalue alignvalue startvalue1] = swalign(frag,tmv((startvalue-incr1):startvalue+length3+incr2),...
'alphabet','nt','gapopen',gapo,'extendgap',gape);
alignseq = nt2int(alignvalue(1,:));

% -- The base position votes are counted before moving to the next fragment -- %
[Avotecount,Cvotecount,Gvotecount,Tvotecount,Xvotecount,sumcount] = votecount(genlength, ...
startvalue,alignseq,Avotecount,Cvotecount,Gvotecount,Tvotecount,Xvotecount,sumcount);
end
end
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Vote-Counting Subroutine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

function [Avotecount,Cvotecount,Gvotecount,Tvotecount,Xvotecount,sumcount] = ...
votecount(genlength,startvalue,alignseq,Avotecount, Cvotecount, ...
Gvotecount,Tvotecount,Xvotecount,sumcount)
% -- The aligned sequences are received from the alignment routine -- %
for k = 1:length(alignseq)
% -- Each base is identified, indexed, and counted -- %
if startvalue+k-1<=genlength
if alignseq(1,k) == 1
Avotecount(1,startvalue+k-1) = Avotecount(1,startvalue+k-1) + 1;
elseif alignseq(1,k) == 2
Cvotecount(1,startvalue+k-1) = Cvotecount(1,startvalue+k-1) + 1;
elseif alignseq(1,k) == 4
Tvotecount(1,startvalue+k-1) = Tvotecount(1,startvalue+k-1) + 1;
elseif alignseq(1,k) == 3
Gvotecount(1,startvalue+k-1) = Gvotecount(1,startvalue+k-1) + 1;
else
Xvotecount(1,startvalue+k-1) = Xvotecount(1,startvalue+k-1) + 1;
end
end
end
% -- Total votes at each position are computed for the assignment subroutine -- %
sumcount(1,:) = Avotecount(1,:) + Cvotecount(1,:) + Tvotecount(1,:) + Gvotecount(1,:);
end
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Base Assignment Subroutine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

function [finalgenome snpgenome] = baseassign1(snpgenome,genlength,...
Avotecount,Cvotecount,Gvotecount,Tvotecount,Xvotecount,...
sumcount,votefrac)
% -- Counts at each position are converted to proportions -- %
votefrac(1,1:genlength) = Avotecount(1,1:genlength)./sumcount(1,1:genlength);
votefrac(2,1:genlength) = Cvotecount(1,1:genlength)./sumcount(1,1:genlength);
votefrac(4,1:genlength) = Tvotecount(1,1:genlength)./sumcount(1,1:genlength);
votefrac(3,1:genlength) = Gvotecount(1,1:genlength)./sumcount(1,1:genlength);
votefrac(5,1:genlength) = Xvotecount(1,1:genlength)./sumcount(1,1:genlength);
% -- The the index of the highest vote proportion determines the base assignment -- %
[maxm index] = max(votefrac,[],1);
% -- Finalgenome (computed) and snpgenome (true) are converted to nucleotides -- %
finalgenome = int2nt(index);
snpgenome = int2nt(snpgenome);
end
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Representative Sensitivity Analysis Script (for Deletion Rate)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

% -- Set sequence constants -- %
genlength = 20000;
errorrate = .001;
mult = 9;
% -- Create matrix of deletion frequencies to be tested -- %
deltest(1,1)= 0.001;
deltest(1,2)= 0.005;
deltest(1,3)= 0.01;
deltest(1,4)= 0.05;
deltest(1,5)= 0.1;
deltest(1,6)= 0.3;
% -- Preallocate arrays -- %
errorc = cell(0,0);
analysis = zeros(length(deltest),7);
l = 1;
trials = 120;
delrate = deltest(1,1);
% -- Test 'm' levels of deletion frequencies with a sample size of 'trials' at each level -- %
for m = 1:length(deltest)
totalerrorrate = zeros(trials,6);
for n = 1:trials
[t1 t2 finalerrorrate snpgenome finalgenome] = genome(genlength,delrate,errorrate,mult);
% -- Record computing time and overall error rate for each trial -- %
totalerrorrate(n,2) = t1;
totalerrorrate(n,3) = t2;
totalerrorrate(n,4) = finalerrorrate;
% -- Record the value and position of each error -- %
for q = 1:length(snpgenome)
if snpgenome(q) - finalgenome(q) ~= 0
errorc{l,1} = q;
errorc{l,2} = snpgenome(q);
errorc{l,3} = finalgenome(q);
l = l+1;
end
end
end
% -- Calculate means and standard deviations for each level of deletion frequency -- %
analysis(m+1,1) = 1/delrate;
analysis(m+1,2) = sum(totalerrorrate(1:trials,2))/trials;
analysis(m+1,3) = std(totalerrorrate(1:trials,2));
analysis(m+1,4) = sum(totalerrorrate(1:trials,3))/trials;
analysis(m+1,5) = std(totalerrorrate(1:trials,3));
analysis(m+1,6) = sum(totalerrorrate(1:trials,4))/trials;
analysis(m+1,7) = std(totalerrorrate(1:trials,4));
delrate = deltest(1,m);
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Monte Carlo Simulation for Dual Camera Peak Detection
1 % Monte Carlo Simulation for Dual Camera Peak Detection
2 % Basic Equation C2/C1- denotes Intensity reading in camera 2 vs. Intensity
3 % reading for camera 1.
4%
5 %--------------------------------------------------------------------6 % Generating n samples for a normal distribution for the wavelegth
7 % intensities picked up by each camera:
8%
ca_cb= (randn(n,1)*std)+mean;
9%
a is the camera number
10 %
b is the peak corresponding to the wavelength
11 %
std is the standard deviation
12 %
mean is the mean
13
n = 100000;%------number of iterations
14
c1_1 = ( randn(n,1)*409.1812)+24198;
15
c2_1 = ( randn(n,1)*3.821595)+226;
16
c1_2 = ( randn(n,1)*395.1607)+28178;
17
c2_2 = ( randn(n,1)*25.25674)+1801;
18
c1_3 = ( randn(n,1)*10.363)+548;
19
c2_3 = ( randn(n,1)*476.074)+25175;
20
c1_4 = ( randn(n,1)*1.675957)+110;
21
c2_4 = ( randn(n,1)*476.9316)+31303;
22 %---------------------------------------------------------------------23 % Simulation run for each peak
24
peak1 = c2_1./c1_1;
25
peak2 = c2_2./c1_2;
26
peak3 = c2_3./c1_3;
27
peak4 = c2_4./c1_4;
28 %---------------------------------------------------------------------29 % Plotting the Histograms
30
[n1, xout1] = hist(log(peak1), 50);
31
[n2, xout2] = hist(log(peak2), 50);
32
[n3, xout3] = hist(log(peak3), 50);
33
[n4, xout4] = hist(log(peak4), 50);
34
35
plot(xout1, n1,'r', xout2, n2, 'g',xout3, n3, 'b', xout4, n4, 'm');
36
37 %---------------------------------------------------------------------38 % Output for each peak
39
peak1_mean = mean(peak1)
40
peak1_std = std(peak1)
41
peak1_err = peak1_std/n^(0.5)% Finds standard error.
42
43
peak2_mean = mean(peak2)
44
peak2_std = std(peak2)
45
peak2_err = peak2_std/n^(0.5)
46
47
peak3_mean = mean(peak3)
48
peak3_std = std(peak3)
49
peak3_err = peak3_std/n^(0.5)
50
51
peak4_mean = mean(peak4)
52
peak4_std = std(peak4)
53
peak4_err = peak4_std/n^(0.5)
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F.1

Case 1

F.2

Case 2

F.3

Case 3

F.4

Case 4

F.5

Case 5

F.6

Case 6

F.7

Case 7

F.8

Case 8

F.9

Case 9

F.10

Case 10

F.11

Case 11

F.12

Case 12

F.13

Growth Case
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NPV @ 30%
NPV @ 25%

Series A @ 31% of Equity
Series B @ 66% of Equity

Income Statement
Revenue
Cost of Sales
Operating, SG&A Expenses
Depreciation
Pre-Tax Income
# Tax @ 40%
Net Income
The two investments
Cash Flow Statement
Cash From Operating Activities
Plus: Depreciation
Changes in Working Capital
(Increase)/Decrease in A/R
(Increase)/Decrease in Inventory
Increase/(Decrease) in A/P
(Increase)/Decrease in C/R
Total Change in Working Capital
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock
Free Cash Flow
Discount Rate @ 30%
% of Design Capacity
Discount Rate @ 25%

Case 1
Year
2012

$ 141.7
$ (1,232.9)
(28.4)
111.0
(184.5)
$ (1,334.8)
(2,676.8)

$ $ 24.5
(73.0)
$ (48.5)
(708.3)

-

$ (1,232.9)
(28.4)
111.0
$ (1,150.3)

$ 762.0

2
3
$ 15,000.0
$ 30,000.0
(643.6)
(988.6)
(2,380.0)
(3,730.0)
(141.7)
(762.0)
11,834.7
24,519.4
(4,733.9)
(9,807.8)
$ 7,100.8
$ 14,711.6
$ (2,692.3) $ (2,800.00)

2011

30% $

$ 4,378.1
10,279.3

$ 15,565.9
30%
100%
25%

-

$ $ -

$ 992.6

4
$ 30,000.0
(988.6)
(3,730.0)
(992.6)
24,288.8
(9,715.5)
$ 14,573.3

2013

$ 4,757.9
10,174.5

$ 15,407.1
30%
100%
25%

-

$ $ -

$ 595.5

5
$ 30,000.0
(988.6)
(3,730.0)
(595.5)
24,685.9
(9,874.3)
$ 14,811.5
Terminal Growth

2014

$ 4,709.3
40,697.9

$ 18,837.3

$ 51,356.9 (Terminal
$ 61,628.2 Value)
30%
100%
25%

0%

6

2015

$ 26,959
Series A MIRR
77%
$ 35,331
Series B MIRR
87%
109.65 $ 3,982.80 $
6,519.51 $ 5,450.04 $ 4,149.57 $ 10,639.92

1,200.0
3,500.0
$ 164.5
$ 6,730.9
$ 14,323.4
50%
30%
30%
0%
50%
100%
50%
25%
25%
Investment Divided Free Cash Flows
$ (1,200.0)
$ 148.0
$ 2,057.4
(3,500.0)
4,445.0
9,458.8

$

1
$ (172.6)
(292.0)
(464.6)
185.8
$ (278.8)
(1,200.00)

2010
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NPV @ 30%
NPV @ 25%

Series A @ 31% of Equity
Series B @ 66% of Equity

Income Statement
Revenue
Cost of Sales
Operating, SG&A Expenses
Depreciation
Pre-Tax Income
# Tax @ 40%
Net Income
The two investments
Cash Flow Statement
Cash From Operating Activities
Plus: Depreciation
Changes in Working Capital
(Increase)/Decrease in A/R
(Increase)/Decrease in Inventory
Increase/(Decrease) in A/P
(Increase)/Decrease in C/R
Total Change in Working Capital
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock
Free Cash Flow
Discount Rate @ 30%
% of Design Capacity
Discount Rate @ 25%

Case 2
Year
2012

$ (1,232.9)
(28.4)
111.0
(184.5)
$ (1,334.8)
(2,676.8)

$ 24.5
(73.0)
$ (48.5)
(708.3)

-

$ (1,232.9)
(28.4)
111.0
$ (1,150.3)

$ 762.0

30% $

$ 4,378.1
10,279.3

$ 15,565.9
30%
100%
25%

-

$ $ -

$ 992.6

4
$ 30,000.0
(988.6)
(3,730.0)
(992.6)
24,288.8
(9,715.5)
$ 14,573.3

2013

$ 4,757.9
10,174.5

$ 15,407.1
30%
100%
25%

-

$ $ -

$ 595.5

5
$ 30,000.0
(988.6)
(3,730.0)
(595.5)
24,685.9
(9,874.3)
$ 14,811.5
Terminal Growth

2014

$ 22,349
Series A MIRR
69%
$ 27,758
Series B MIRR
76%
109.65 $ 3,982.80 $ 6,519.51 $ 5,450.04 $ 4,149.57 $

1,200.0
3,500.0
$ 164.5
$ 6,730.9
$ 14,323.4
50%
30%
30%
0%
50%
100%
50%
25%
25%
Investment Divided Free Cash Flows
$ (1,200.0)
$ 148.0
$ 2,057.4
(3,500.0)
4,445.0
9,458.8

$ 141.7

2
3
$ 15,000.0
$ 30,000.0
(643.6)
(988.6)
(2,380.0)
(3,730.0)
(141.7)
(762.0)
11,834.7
24,519.4
(4,733.9)
(9,807.8)
$ 7,100.8
$ 14,711.6
$ (2,692.3) $ (2,800.00)

2011

$ -

1
$ (172.6)
(292.0)
(464.6)
185.8
$ (278.8)
$ (1,200.00)

2010

6,029.29

$ 4,709.3
21,620.8

$ 10,007.3

$ 29,102.2 (Terminal
$ 32,740.0 Value)
30%
100%
25%

-15%

6

2015
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NPV @ 30%
NPV @ 25%

Series A @ 31% of Equity
Series B @ 66% of Equity

Income Statement
Revenue
Cost of Sales
Operating, SG&A Expenses
Depreciation
Pre-Tax Income
# Tax @ 40%
Net Income
The two investments
Cash Flow Statement
Cash From Operating Activities
Plus: Depreciation
Changes in Working Capital
(Increase)/Decrease in A/R
(Increase)/Decrease in Inventory
Increase/(Decrease) in A/P
(Increase)/Decrease in C/R
Total Change in Working Capital
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock
Free Cash Flow
Discount Rate @ 30%
% of Design Capacity
Discount Rate @ 25%

Case 3
Year
2012

$ 141.7
$ (1,232.9)
(28.4)
111.0
(184.5)
$ (1,334.8)
(2,676.8)

$ $ 24.5
(73.0)
$ (48.5)
(708.3)

-

$ (1,232.9)
(28.4)
111.0
$ (1,150.3)

$ 762.0

2
3
$ 15,000.0
$ 30,000.0
(643.6)
(988.6)
(2,380.0)
(3,730.0)
(141.7)
(762.0)
11,834.7
24,519.4
(4,733.9)
(9,807.8)
$ 7,100.8
$ 14,711.6
$ (2,692.3) $ (2,800.00)

2011

30% $

$ 4,378.1
10,279.3

$ 15,565.9
30%
100%
25%

-

$ $ -

$ 992.6

4
$ 30,000.0
(988.6)
(3,730.0)
(992.6)
24,288.8
(9,715.5)
$ 14,573.3

2013

$ 4,757.9
10,174.5

$ 15,407.1
30%
100%
25%

-

$ $ -

$ 595.5

5
$ 30,000.0
(988.6)
(3,730.0)
(595.5)
24,685.9
(9,874.3)
$ 14,811.5
Terminal Growth

2014

$ 16,670
Series A MIRR
58%
$ 19,619
Series B MIRR
62%
109.65 $ 3,982.80 $ 6,519.51 $ 5,450.04 $ 4,149.57 $

1,200.0
3,500.0
$ 164.5
$ 6,730.9
$ 14,323.4
50%
30%
30%
0%
50%
100%
50%
25%
25%
Investment Divided Free Cash Flows
$ (1,200.0)
$ 148.0
$ 2,057.4
(3,500.0)
4,445.0
9,458.8

$

1
$ (172.6)
(292.0)
(464.6)
185.8
$ (278.8)
(1,200.00)

2010

350.66

$ 4,709.3
1,117.7

$ 517.3

$ 1,692.6 (Terminal
$ 1,692.6 Value)
30%
100%
25%

-15%

6

2015
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NPV @ 30%
NPV @ 25%

Series A @ 31% of Equity
Series B @ 66% of Equity

Income Statement
Revenue
Cost of Sales
Operating, SG&A Expenses
Depreciation
Pre-Tax Income
# Tax @ 40%
Net Income
The two investments
Cash Flow Statement
Cash From Operating Activities
Plus: Depreciation
Changes in Working Capital
(Increase)/Decrease in A/R
(Increase)/Decrease in Inventory
Increase/(Decrease) in A/P
(Increase)/Decrease in C/R
Total Change in Working Capital
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock
Free Cash Flow
Discount Rate @ 30%
% of Design Capacity
Discount Rate @ 25%

Case 4
Year
2011

2012

$ (739.7)
(17.0)
66.6
(184.5)
$ (874.7)
(2,676.8)

$ 24.5
(73.0)
$ (48.5)
(708.3)

-

$ (986.3)
(22.7)
88.8
$ (920.2)

$ 762.0

30% $

$ 2,984.4
9,823.6

$ 14,875.7
30%
100%
25%

-

$ (739.7)
(17.0)
66.6
$ (690.2)

$ 992.6

4
$ 30,000.0
(988.6)
(3,730.0)
(992.6)
24,288.8
(9,715.5)
$ 14,573.3

2013

$ 4,546.9
10,174.5

$ 15,407.1
30%
100%
25%

-

$ $ -

$ 595.5

5
$ 30,000.0
(988.6)
(3,730.0)
(595.5)
24,685.9
(9,874.3)
$ 14,811.5
Terminal Growth

2014

$ 4,709.3
40,697.9

$ 18,837.3

$ 51,356.9 (Terminal
$ 61,628.2 Value)
30%
100%
25%

0%

6

2015

$ 23,025
Series A MIRR
75%
$ 30,964
Series B MIRR
84%
109.65 $ 2,365.59 $ 4,444.07 $ 5,208.40 $ 4,149.57 $ 10,639.92

1,200.0
3,500.0
$ 164.5
$ 3,997.8
$ 9,763.6
50%
30%
30%
0%
30%
70%
50%
25%
25%
Investment Divided Free Cash Flows
$ (1,200.0)
$ 148.0
$ 1,222.0
(3,500.0)
2,640.1
6,447.7

$ 141.7

$ -

1
2
3
$ $ 9,000.0
$ 21,000.0
(172.6)
(505.6)
(781.6)
(292.0)
(1,840.0)
(2,920.0)
(141.7)
(762.0)
(464.6)
6,512.7
16,536.4
185.8
(2,605.1)
(6,614.6)
$ (278.8) $ 3,907.6
$ 9,921.8
$ (1,200.00) $ (2,692.3) $ (2,800.00)

2010
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NPV @ 30%
NPV @ 25%

Series A @ 31% of Equity
Series B @ 66% of Equity

Income Statement
Revenue
Cost of Sales
Operating, SG&A Expenses
Depreciation
Pre-Tax Income
# Tax @ 40%
Net Income
The two investments
Cash Flow Statement
Cash From Operating Activities
Plus: Depreciation
Changes in Working Capital
(Increase)/Decrease in A/R
(Increase)/Decrease in Inventory
Increase/(Decrease) in A/P
(Increase)/Decrease in C/R
Total Change in Working Capital
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock
Free Cash Flow
Discount Rate @ 30%
% of Design Capacity
Discount Rate @ 25%

Case 5
Year
2011

2012

$ (739.7)
(17.0)
66.6
(184.5)
$ (874.7)
(2,676.8)

$ 24.5
(73.0)
$ (48.5)
(708.3)

-

$ (986.3)
(22.7)
88.8
$ (920.2)

$ 762.0

30% $

$ 2,984.4
9,823.6

$ 14,875.7
30%
100%
25%

-

$ (739.7)
(17.0)
66.6
$ (690.2)

$ 992.6

4
$ 30,000.0
(988.6)
(3,730.0)
(992.6)
24,288.8
(9,715.5)
$ 14,573.3

2013

$ 4,546.9
10,174.5

$ 15,407.1
30%
100%
25%

-

$ $ -

$ 595.5

5
$ 30,000.0
(988.6)
(3,730.0)
(595.5)
24,685.9
(9,874.3)
$ 14,811.5
Terminal Growth

2014

$ 18,414
Series A MIRR
66%
$ 23,392
Series B MIRR
73%
109.65 $ 2,365.59 $ 4,444.07 $ 5,208.40 $ 4,149.57 $

1,200.0
3,500.0
$ 164.5
$ 3,997.8
$ 9,763.6
50%
30%
30%
0%
30%
70%
50%
25%
25%
Investment Divided Free Cash Flows
$ (1,200.0)
$ 148.0
$ 1,222.0
(3,500.0)
2,640.1
6,447.7

$ 141.7

$ -

1
2
3
$ $ 9,000.0
$ 21,000.0
(172.6)
(505.6)
(781.6)
(292.0)
(1,840.0)
(2,920.0)
(141.7)
(762.0)
(464.6)
6,512.7
16,536.4
185.8
(2,605.1)
(6,614.6)
$ (278.8) $ 3,907.6
$ 9,921.8
$ (1,200.00) $ (2,692.3) $ (2,800.00)

2010

6,029.29

$ 4,709.3
21,620.8

$ 10,007.3

$ 29,102.2 (Terminal
$ 32,740.0 Value)
30%
100%
25%

-15%

6

2015
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NPV @ 30%
NPV @ 25%

Series A @ 31% of Equity
Series B @ 66% of Equity

Income Statement
Revenue
Cost of Sales
Operating, SG&A Expenses
Depreciation
Pre-Tax Income
# Tax @ 40%
Net Income
The two investments
Cash Flow Statement
Cash From Operating Activities
Plus: Depreciation
Changes in Working Capital
(Increase)/Decrease in A/R
(Increase)/Decrease in Inventory
Increase/(Decrease) in A/P
(Increase)/Decrease in C/R
Total Change in Working Capital
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock
Free Cash Flow
Discount Rate @ 30%
% of Design Capacity
Discount Rate @ 25%

Case 6
Year
2012

$ 141.7
$ (739.7)
(17.0)
66.6
(184.5)
$ (874.7)
(2,676.8)

$ $ 24.5
(73.0)
$ (48.5)
(708.3)

-

$ (986.3)
(22.7)
88.8
$ (920.2)

$ 762.0

30% $

$ 2,984.4
9,823.6

$ 14,875.7
30%
100%
25%

-

$ (739.7)
(17.0)
66.6
$ (690.2)

$ 992.6

4
$ 30,000.0
(988.6)
(3,730.0)
(992.6)
24,288.8
(9,715.5)
$ 14,573.3

2013

$ 4,546.9
10,174.5

$ 15,407.1
30%
100%
25%

-

$ $ -

$ 595.5

5
$ 30,000.0
(988.6)
(3,730.0)
(595.5)
24,685.9
(9,874.3)
$ 14,811.5
Terminal Growth

2014

$ 12,736
Series A MIRR
53%
$ 15,253
Series B MIRR
57%
109.65 $ 2,365.59 $ 4,444.07 $ 5,208.40 $ 4,149.57 $

1,200.0
3,500.0
$ 164.5
$ 3,997.8
$ 9,763.6
50%
30%
30%
0%
30%
70%
50%
25%
25%
Investment Divided Free Cash Flows
$ (1,200.0)
$ 148.0
$ 1,222.0
(3,500.0)
2,640.1
6,447.7

$

2011

1
2
3
$ $ 9,000.0
$ 21,000.0
(172.6)
(505.6)
(781.6)
(292.0)
(1,840.0)
(2,920.0)
(141.7)
(762.0)
(464.6)
6,512.7
16,536.4
185.8
(2,605.1)
(6,614.6)
$ (278.8) $ 3,907.6
$ 9,921.8
(1,200.00) $ (2,692.3) $ (2,800.00)

2010

350.66

$ 4,709.3
1,117.7

$ 517.3

$ 1,692.6 (Terminal
$ 1,692.6 Value)
30%
100%
25%

-15%

6

2015
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NPV @ 30%
NPV @ 25%

Series A @ 39% of Equity
Series B @ 56% of Equity

Income Statement
Revenue
Cost of Sales
Operating, SG&A Expenses
Depreciation
Pre-Tax Income
# Tax @ 40%
Net Income
The two investments
Cash Flow Statement
Cash From Operating Activities
Plus: Depreciation
Changes in Working Capital
(Increase)/Decrease in A/R
(Increase)/Decrease in Inventory
Increase/(Decrease) in A/P
(Increase)/Decrease in C/R
Total Change in Working Capital
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock
Free Cash Flow
Discount Rate @ 30%
% of Design Capacity
Discount Rate @ 25%

Case 7
Year
2012

$ 141.7
$ $ -

$ $ 24.5
(73.0)
$ (48.5)
(708.3)

(2,676.8)

$ (1,232.9)
(28.4)
111.0
(184.5)
$ (1,334.8)

$ 226.7

30% $

$ 2,651.4
8,774.9

$ 14,287.1
30%
100%
25%

-

$ (1,232.9)
(28.4)
111.0
$ (1,150.3)

$ 671.4

3
$ 30,000.0
(988.6)
(3,730.0)
(671.4)
24,610.0
(9,844.0)
$ 14,766.0

2013

$ 5,599.6
8,697.5

$ 15,544.1
30%
100%
25%

-

$ $ -

$ 938.2

4
$ 30,000.0
(988.6)
(3,730.0)
(938.2)
24,343.2
(9,737.3)
$ 14,605.9

2014

$ 6,092.3
34,790.1

$ 15,407.1
30%
100%
25%

-

$ $ -

$ 595.5

5
$ 30,000.0
(988.6)
(3,730.0)
(595.5)
24,685.9
(9,874.3)
$ 14,811.5
Terminal Growth

2015

$ 6,038.6

$ 24,154.3

$ 51,356.9 (Terminal
$ 61,628.2 Value)
30%
100%
25%

0%

6

2016

$ 26,733
Series A MIRR
58%
$ 35,103
Series B MIRR
81%
109.65 $ (222.10) $ 4,002.92 $ 6,503.01 $ 5,442.42 $ 4,149.57 $ 10,639.92

1,200.0
3,500.0
$ 164.5
$ (222.1)
$ 6,764.9
50%
50%
30%
0%
0%
50%
50%
50%
25%
Investment Divided Free Cash Flows
$ (1,200.0)
$ 148.0
$ (199.9)
(3,500.0)
3,818.9
8,065.3

$

2011

1
2
$ $ $ 15,000.0
(172.6)
(172.6)
(643.6)
(292.0)
(292.0)
(2,380.0)
(141.7)
(226.7)
(464.6)
(606.3)
11,749.7
185.8
242.5
(4,699.9)
$ (278.8)
$ (363.8)
$ 7,049.8
(1,200.00) $ (2,692.3) $ (2,800.00)

2010
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NPV @ 30%
NPV @ 25%

Series A @ 39% of Equity
Series B @ 56% of Equity

Income Statement
Revenue
Cost of Sales
Operating, SG&A Expenses
Depreciation
Pre-Tax Income
# Tax @ 40%
Net Income
The two investments
Cash Flow Statement
Cash From Operating Activities
Plus: Depreciation
Changes in Working Capital
(Increase)/Decrease in A/R
(Increase)/Decrease in Inventory
Increase/(Decrease) in A/P
(Increase)/Decrease in C/R
Total Change in Working Capital
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock
Free Cash Flow
Discount Rate @ 30%
% of Design Capacity
Discount Rate @ 25%

Case 8
Year
2012

$ 141.7
$ $ -

$ $ 24.5
(73.0)
$ (48.5)
(708.3)

(2,676.8)

$ (1,232.9)
(28.4)
111.0
(184.5)
$ (1,334.8)

$ 226.7

30% $

$ 2,651.4
8,774.9

$ 14,287.1
30%
100%
25%

-

$ (1,232.9)
(28.4)
111.0
$ (1,150.3)

$ 671.4

3
$ 30,000.0
(988.6)
(3,730.0)
(671.4)
24,610.0
(9,844.0)
$ 14,766.0

2013

$ 5,599.6
8,697.5

$ 15,544.1
30%
100%
25%

-

$ $ -

$ 938.2

4
$ 30,000.0
(988.6)
(3,730.0)
(938.2)
24,343.2
(9,737.3)
$ 14,605.9

2014

$ 6,092.3
18,482.3

$ 15,407.1
30%
100%
25%

-

$ $ -

$ 595.5

5
$ 30,000.0
(988.6)
(3,730.0)
(595.5)
24,685.9
(9,874.3)
$ 14,811.5
Terminal Growth

2015

$ 22,122
Series A MIRR
58%
$ 27,530
Series B MIRR
71%
109.65 $ (222.10) $ 4,002.92 $ 6,503.01 $ 5,442.42 $ 4,149.57 $

1,200.0
3,500.0
$ 164.5
$ (222.1)
$ 6,764.9
50%
50%
30%
0%
0%
50%
50%
50%
25%
Investment Divided Free Cash Flows
$ (1,200.0)
$ 148.0
$ (199.9)
(3,500.0)
3,818.9
8,065.3

$

2011

1
2
$ $ $ 15,000.0
(172.6)
(172.6)
(643.6)
(292.0)
(292.0)
(2,380.0)
(141.7)
(226.7)
(464.6)
(606.3)
11,749.7
185.8
242.5
(4,699.9)
$ (278.8)
$ (363.8)
$ 7,049.8
(1,200.00) $ (2,692.3) $ (2,800.00)

2010

6,029.29

$ 6,038.6

$ 12,832.0

$ 29,102.2 (Terminal
$ 32,740.0 Value)
30%
100%
25%

-15%

6

2016
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NPV @ 30%
NPV @ 25%

Series A @ 39% of Equity
Series B @ 56% of Equity

Income Statement
Revenue
Cost of Sales
Operating, SG&A Expenses
Depreciation
Pre-Tax Income
# Tax @ 40%
Net Income
The two investments
Cash Flow Statement
Cash From Operating Activities
Plus: Depreciation
Changes in Working Capital
(Increase)/Decrease in A/R
(Increase)/Decrease in Inventory
Increase/(Decrease) in A/P
(Increase)/Decrease in C/R
Total Change in Working Capital
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock
Free Cash Flow
Discount Rate @ 30%
% of Design Capacity
Discount Rate @ 25%

Case 9
Year
2011

2012

$ $ -

$ 24.5
(73.0)
$ (48.5)
(708.3)

(2,676.8)

$ (1,232.9)
(28.4)
111.0
(184.5)
$ (1,334.8)

$ 226.7

30% $

$ 2,651.4
8,774.9

$ 14,287.1
30%
100%
25%

-

$ (1,232.9)
(28.4)
111.0
$ (1,150.3)

$ 671.4

3
$ 30,000.0
(988.6)
(3,730.0)
(671.4)
24,610.0
(9,844.0)
$ 14,766.0

2013

$ 5,599.6
8,697.5

$ 15,544.1
30%
100%
25%

-

$ $ -

$ 938.2

4
$ 30,000.0
(988.6)
(3,730.0)
(938.2)
24,343.2
(9,737.3)
$ 14,605.9

2014

$ 6,092.3
955.5

$ 15,407.1
30%
100%
25%

-

$ $ -

$ 595.5

5
$ 30,000.0
(988.6)
(3,730.0)
(595.5)
24,685.9
(9,874.3)
$ 14,811.5
Terminal Growth

2015

$ 16,444
Series A MIRR
58%
$ 19,391
Series B MIRR
57%
109.65 $ (222.10) $ 4,002.92 $ 6,503.01 $ 5,442.42 $ 4,149.57 $

1,200.0
3,500.0
$ 164.5
$ (222.1)
$ 6,764.9
50%
50%
30%
0%
0%
50%
50%
50%
25%
Investment Divided Free Cash Flows
$ (1,200.0)
$ 148.0
$ (199.9)
(3,500.0)
3,818.9
8,065.3

$ 141.7

$ -

1
2
$ $ $ 15,000.0
(172.6)
(172.6)
(643.6)
(292.0)
(292.0)
(2,380.0)
(141.7)
(226.7)
(464.6)
(606.3)
11,749.7
185.8
242.5
(4,699.9)
$ (278.8) $ (363.8)
$ 7,049.8
$ (1,200.00) ######## $ (2,800.00)

2010

350.66

$ 6,038.6

$ 663.4

$ 1,692.6 (Terminal
$ 1,692.6 Value)
30%
100%
25%

-15%

6

2016
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NPV @ 30%
NPV @ 25%

Series A @ 39% of Equity
Series B @ 56% of Equity

Income Statement
Revenue
Cost of Sales
Operating, SG&A Expenses
Depreciation
Pre-Tax Income
# Tax @ 40%
Net Income
The two investments
Cash Flow Statement
Cash From Operating Activities
Plus: Depreciation
Changes in Working Capital
(Increase)/Decrease in A/R
(Increase)/Decrease in Inventory
Increase/(Decrease) in A/P
(Increase)/Decrease in C/R
Total Change in Working Capital
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock
Free Cash Flow
Discount Rate @ 30%
% of Design Capacity
Discount Rate @ 25%

Case 10
Year
2012

$ 141.7
$ $ -

$ $ 24.5
(73.0)
$ (48.5)
(708.3)

(2,676.8)

$ (739.7)
(17.0)
66.6
(184.5)
$ (874.7)

$ 226.7

30% $

$ 1,580.2
8,385.3

$ 9,727.4
30%
70%
25%

-

$ (986.3)
(22.7)
88.8
$ (920.2)

$ 671.4

3
$ 21,000.0
(781.6)
(2,920.0)
(671.4)
16,627.0
(6,650.8)
$ 9,976.2

2013

$ 3,812.5
8,697.5

$ 14,853.9
30%
100%
25%

-

$ (739.7)
(17.0)
66.6
$ (690.2)

$ 938.2

4
$ 30,000.0
(988.6)
(3,730.0)
(938.2)
24,343.2
(9,737.3)
$ 14,605.9

2014

$ 5,821.8
34,790.1

$ 15,407.1
30%
100%
25%

-

$ $ -

$ 595.5

5
$ 30,000.0
(988.6)
(3,730.0)
(595.5)
24,685.9
(9,874.3)
$ 14,811.5
Terminal Growth

2015

$ 6,038.6

$ 24,154.3

$ 51,356.9 (Terminal
$ 61,628.2 Value)
30%
100%
25%

0%

6

2016

$ 22,799
Series A MIRR
54%
$ 30,737
Series B MIRR
78%
109.65 $ (222.10) $ 2,385.70 $ 4,427.57 $ 5,200.78 $ 4,149.57 $ 10,639.92

1,200.0
3,500.0
$ 164.5
$ (222.1) $ 4,031.8
50%
50%
30%
0%
0%
30%
50%
50%
25%
Investment Divided Free Cash Flows
$ (1,200.0)
$ 148.0
$ (199.9)
(3,500.0)
2,276.0
5,491.3

$

2011

1
2
$ $ $ 9,000.0
(172.6)
(172.6)
(505.6)
(292.0)
(292.0)
(1,840.0)
(141.7)
(226.7)
(464.6)
(606.3)
6,427.7
185.8
242.5
(2,571.1)
$ (278.8) $ (363.8) $ 3,856.6
(1,200.00) ######## $(2,800.00)

2010
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NPV @ 30%
NPV @ 25%

Series A @ 39% of Equity
Series B @ 56% of Equity

Income Statement
Revenue
Cost of Sales
Operating, SG&A Expenses
Depreciation
Pre-Tax Income
# Tax @ 40%
Net Income
The two investments
Cash Flow Statement
Cash From Operating Activities
Plus: Depreciation
Changes in Working Capital
(Increase)/Decrease in A/R
(Increase)/Decrease in Inventory
Increase/(Decrease) in A/P
(Increase)/Decrease in C/R
Total Change in Working Capital
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock
Free Cash Flow
Discount Rate @ 30%
% of Design Capacity
Discount Rate @ 25%

Case 11
Year
2011

2012

$ $ -

$ 24.5
(73.0)
$ (48.5)
(708.3)

(2,676.8)

$ (739.7)
(17.0)
66.6
(184.5)
$ (874.7)

$ 226.7

30% $

$ 1,580.2
8,385.3

$ 9,727.4
30%
70%
25%

-

$ (986.3)
(22.7)
88.8
$ (920.2)

$ 671.4

3
$ 21,000.0
(781.6)
(2,920.0)
(671.4)
16,627.0
(6,650.8)
$ 9,976.2

2013

$ 3,812.5
8,697.5

$ 14,853.9
30%
100%
25%

-

$ (739.7)
(17.0)
66.6
$ (690.2)

$ 938.2

4
$ 30,000.0
(988.6)
(3,730.0)
(938.2)
24,343.2
(9,737.3)
$ 14,605.9

2014

$ 5,821.8
18,482.3

$ 15,407.1
30%
100%
25%

-

$ $ -

$ 595.5

5
$ 30,000.0
(988.6)
(3,730.0)
(595.5)
24,685.9
(9,874.3)
$ 14,811.5
Terminal Growth

2015

$ 18,188
Series A MIRR
54%
$ 23,164
Series B MIRR
67%
109.65 $ (222.10) $ 2,385.70 $ 4,427.57 $ 5,200.78 $ 4,149.57 $

1,200.0
3,500.0
$ 164.5
$ (222.1) $ 4,031.8
50%
50%
30%
0%
0%
30%
50%
50%
25%
Investment Divided Free Cash Flows
$ (1,200.0)
$ 148.0
$ (199.9)
(3,500.0)
2,276.0
5,491.3

$ 141.7

$ -

1
2
$ $ $ 9,000.0
(172.6)
(172.6)
(505.6)
(292.0)
(292.0)
(1,840.0)
(141.7)
(226.7)
(464.6)
(606.3)
6,427.7
185.8
242.5
(2,571.1)
$ (278.8) $ (363.8) $ 3,856.6
$ (1,200.00) ######## $(2,800.00)

2010

6,029.29

$ 6,038.6

$ 12,832.0

$ 29,102.2 (Terminal
$ 32,740.0 Value)
30%
100%
25%

-15%

6

2016
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NPV @ 30%
NPV @ 25%

Series A @ 39% of Equity
Series B @ 56% of Equity

Income Statement
Revenue
Cost of Sales
Operating, SG&A Expenses
Depreciation
Pre-Tax Income
# Tax @ 40%
Net Income
The two investments
Cash Flow Statement
Cash From Operating Activities
Plus: Depreciation
Changes in Working Capital
(Increase)/Decrease in A/R
(Increase)/Decrease in Inventory
Increase/(Decrease) in A/P
(Increase)/Decrease in C/R
Total Change in Working Capital
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock
Free Cash Flow
Discount Rate @ 30%
% of Design Capacity
Discount Rate @ 25%

Case 12
Year
2011

2012

$ $ -

$ 24.5
(73.0)
$ (48.5)
(708.3)

(2,676.8)

$ (739.7)
(17.0)
66.6
(184.5)
$ (874.7)

$ 226.7

30% $

$ 1,580.2
8,385.3

$ 9,727.4
30%
70%
25%

-

$ (986.3)
(22.7)
88.8
$ (920.2)

$ 671.4

3
$ 21,000.0
(781.6)
(2,920.0)
(671.4)
16,627.0
(6,650.8)
$ 9,976.2

2013

$ 3,812.5
8,697.5

$ 14,853.9
30%
100%
25%

-

$ (739.7)
(17.0)
66.6
$ (690.2)

$ 938.2

4
$ 30,000.0
(988.6)
(3,730.0)
(938.2)
24,343.2
(9,737.3)
$ 14,605.9

2014

$ 5,821.8
955.5

$ 15,407.1
30%
100%
25%

-

$ $ -

$ 595.5

5
$ 30,000.0
(988.6)
(3,730.0)
(595.5)
24,685.9
(9,874.3)
$ 14,811.5
Terminal Growth

2015

$ 12,510
Series A MIRR
54%
$ 15,025
Series B MIRR
52%
109.65 $ (222.10) $ 2,385.70 $ 4,427.57 $ 5,200.78 $ 4,149.57 $

1,200.0
3,500.0
$ 164.5
$ (222.1) $ 4,031.8
50%
50%
30%
0%
0%
30%
50%
50%
25%
Investment Divided Free Cash Flows
$ (1,200.0)
$ 148.0
$ (199.9)
(3,500.0)
2,276.0
5,491.3

$ 141.7

$ -

1
2
$ $ $ 9,000.0
(172.6)
(172.6)
(505.6)
(292.0)
(292.0)
(1,840.0)
(141.7)
(226.7)
(464.6)
(606.3)
6,427.7
185.8
242.5
(2,571.1)
$ (278.8) $ (363.8) $ 3,856.6
$ (1,200.00) ######## $(2,800.00)

2010

350.66

$ 6,038.6

$ 663.4

$ 1,692.6 (Terminal
$ 1,692.6 Value)
30%
100%
25%

-15%

6

2016
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NPV @ 30%
NPV @ 25%

Series A @ 31% of Equity
Series B @ 66% of Equity

Income Statement
Revenue
Cost of Sales
Operating, SG&A Expenses
Depreciation
Pre-Tax Income
# Tax @ 40%
Net Income
The two investments
Cash Flow Statement
Cash From Operating Activities
Plus: Depreciation
Changes in Working Capital
(Increase)/Decrease in A/R
(Increase)/Decrease in Inventory
Increase/(Decrease) in A/P
(Increase)/Decrease in C/R
Total Change in Working Capital
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock
Free Cash Flow
Discount Rate @ 30%
% of Design Capacity
Discount Rate @ 25%

Growth Case
Year
2012

$ (1,232.9)
(28.4)
111.0
(184.5)
$ (1,334.8)
(2,676.8)

$ 24.5
(73.0)
$ (48.5)
(708.3)

-

$ (1,232.9)
(28.4)
111.0
$ (1,150.3)

$ 762.0

30% $

$ 4,378.1
14,587.5

$ 22,089.6
30%
150%
25%

-

$ (1,232.9)
(28.4)
111.0
$ (1,150.3)

$ 992.6

4
$ 45,000.0
(1,333.6)
(5,595.0)
(992.6)
37,078.8
(14,831.5)
$ 22,247.3

2013

$ 6,751.9
21,704.4

$ 32,866.6
30%
225%
25%

-

$ (1,849.3)
(42.5)
166.4
$ (1,725.4)

$ 595.5

5
$ 67,500.0
(1,851.1)
(8,392.5)
(595.5)
56,660.9
(22,664.3)
$ 33,996.5
Terminal Growth

2014

$ 10,046.0
86,817.6

$ 40,184.1

$ 109,555.5 (Terminal
$ 131,466.6 Value)
30%
225%
50%
25%

0%

6

2015

$ 46,003
Series A MIRR
95%
$ 62,032
Series B MIRR
110%
109.65 $ 3,982.80 $
6,519.51 $ 7,734.18 $ 8,851.94 $ 22,697.29

1,200.0
3,500.0
$ 164.5
$ 6,730.9
$ 14,323.4
50%
30%
30%
0%
50%
100%
50%
25%
25%
Investment Divided Free Cash Flows
$ (1,200.0)
$ 148.0
$ 2,057.4
(3,500.0)
4,445.0
9,458.8

$ 141.7

2
3
$ 15,000.0
$ 30,000.0
(643.6)
(988.6)
(2,380.0)
(3,730.0)
(141.7)
(762.0)
11,834.7
24,519.4
(4,733.9)
(9,807.8)
$ 7,100.8
$ 14,711.6
$ (2,692.3) $ (2,800.00)

2011

$ -

1
$ (172.6)
(292.0)
(464.6)
185.8
$ (278.8)
$ (1,200.00)

2010

Appendix F: Financial Pro Forma
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